
<p><strong>Psilocybin</strong>{{#tag:ref|Synonyms and alternate spellings include: psilocybine, psilocibin, psilocybinum, psilotsibin, psilocin phosphate ester, <em>teonanacatl</em>, and Indocybin.<a href="#fn1" class="footnote-ref" id="fnref1"><sup>1</sup></a>|group=nb}} ( ) is a naturally occurring <a href="Psychedelic_drug" title="wikilink">psychedelic</a> compound produced by over <a href="List_of_Psilocybin_mushrooms" title="wikilink">200 species</a> of <a href="mushroom" title="wikilink">mushrooms</a>, collectively known as <a href="psilocybin_mushrooms" title="wikilink">psilocybin mushrooms</a>. The most potent are members of the genus <em><a href="Psilocybe" class="uri" title="wikilink">Psilocybe</a></em>, such as <em><a href="Psilocybe_azurescens" title="wikilink">P. azurescens</a></em>, <em><a href="Psilocybe_semilanceata" title="wikilink">P. semilanceata</a></em>, and <em><a href="Psilocybe_cyanescens" title="wikilink">P. cyanescens</a></em>, but psilocybin has also been isolated from about a dozen other <a href="genera" class="uri" title="wikilink">genera</a>. As a <a href="prodrug" class="uri" title="wikilink">prodrug</a>, psilocybin is quickly converted by the body to <a href="psilocin" class="uri" title="wikilink">psilocin</a>, which has mind-altering effects similar to those of <a href="LSD" class="uri" title="wikilink">LSD</a> and <a href="mescaline" class="uri" title="wikilink">mescaline</a>. The effects can include <a href="euphoria" class="uri" title="wikilink">euphoria</a>, visual and mental <a href="hallucination" title="wikilink">hallucinations</a>, changes in <a href="perception" class="uri" title="wikilink">perception</a>, a distorted <a href="time_perception" title="wikilink">sense of time</a>, and spiritual experiences, as well as adverse reactions such as <a href="nausea" class="uri" title="wikilink">nausea</a> and <a href="panic_attack" title="wikilink">panic attacks</a>.</p>
<p>Imagery found on prehistoric <a href="mural" title="wikilink">murals</a> and <a href="rock_painting" title="wikilink">rock paintings</a> of modern-day Spain and Algeria suggest that human usage of psilocybin mushrooms dates back thousands of years. In <a href="Mesoamerica" class="uri" title="wikilink">Mesoamerica</a>, the mushrooms had long been consumed in <a href="spirituality" title="wikilink">spiritual</a> and <a href="divination" title="wikilink">divinatory</a> ceremonies before Spanish chroniclers first documented their use in the 16th century. In a 1957 <em><a href="Life_(magazine)" title="wikilink">Life</a></em> magazine article, American banker and <a href="ethnomycology" title="wikilink">ethnomycologist</a>  described his experiences ingesting psilocybin-containing mushrooms during a traditional ceremony in Mexico, introducing the drug to popular culture. Shortly afterward, the Swiss chemist <a href="Albert_Hofmann" title="wikilink">Albert Hofmann</a> isolated the active principle psilocybin from the mushroom <em><a href="Psilocybe_mexicana" title="wikilink">Psilocybe mexicana</a></em>. Hofmann's employer <a href="Sandoz" class="uri" title="wikilink">Sandoz</a> marketed and sold pure psilocybin to physicians and clinicians worldwide for use in <a href="Psychedelic_therapy#Psycholytic_therapy" title="wikilink">psychedelic psychotherapy</a>. Although increasingly restrictive drug laws of the late 1960s curbed scientific research into the effects of psilocybin and other hallucinogens, its popularity as an <a href="entheogen" class="uri" title="wikilink">entheogen</a> (spirituality-enhancing agent) grew in the next decade, largely owing to the increased availability of information on how to cultivate psilocybin mushrooms.</p>
<p>Some users of the drug consider it an entheogen and a tool to supplement practices for <a href="Transcendence_(religion)" title="wikilink">transcendence</a>, including <a href="meditation" class="uri" title="wikilink">meditation</a> and <a href="psychonautics" class="uri" title="wikilink">psychonautics</a>. The intensity and duration of the effects of psilocybin are variable, depending on species or <a href="cultivar" class="uri" title="wikilink">cultivar</a> of mushrooms, dosage, individual physiology, and <a href="set_and_setting" title="wikilink">set and setting</a>, as was shown in experiments led by <a href="Timothy_Leary" title="wikilink">Timothy Leary</a> at <a href="Harvard_University" title="wikilink">Harvard University</a> in the early 1960s. Once ingested, psilocybin is rapidly metabolized to psilocin, which then acts on <a href="serotonin_receptor" title="wikilink">serotonin receptors</a> in the brain. The mind-altering effects of psilocybin typically last from two to six hours; however, to individuals under the influence of psilocybin, the effects may seem to last much longer, since the drug can distort the perception of time. Psilocybin has a low <a href="toxicity" class="uri" title="wikilink">toxicity</a> and a relatively low harm potential, and reports of lethal doses of the drug are rare. Several modern <a href="bioanalysis" title="wikilink">bioanalytical</a> methods have been adapted to rapidly and accurately screen the levels of psilocybin in mushroom samples and body fluids. Since the 1990s, there has been a renewal of scientific research into the potential medical and psychological therapeutic benefits of psilocybin for treating conditions including <a href="obsessive-compulsive_disorder" title="wikilink">obsessive-compulsive disorder</a>, <a href="cluster_headache" title="wikilink">cluster headaches</a>, and anxiety related to <a href="terminal_illness" title="wikilink">terminal</a> cancer. Possession of psilocybin-containing mushrooms has been outlawed in most countries, and it has been classified as a <a href="Single_Convention_on_Narcotic_Drugs#Schedules_of_drugs" title="wikilink">scheduled drug</a> by many national <a href="Prohibition_of_drugs" title="wikilink">drug laws</a>.</p>
<h2 id="history">History</h2>
<h3 id="early">Early</h3>
<p><img src="Psilocybe_Mushrooms_statues.jpg" title="fig:Mayan &quot;mushroom stones&quot; of Guatemala" alt="Mayan &quot;mushroom stones&quot; of Guatemala" width="240" /> There is evidence to suggest that psychoactive mushrooms have been used by humans in religious ceremonies for thousands of years. Murals dated 7000 to 9000 <a href="BCE" class="uri" title="wikilink">BCE</a> found in the <a href="Sahara_desert" title="wikilink">Sahara desert</a> in southeast Algeria depict horned beings dressed as dancers, clothed in garb decorated with geometrical designs, and holding mushroom-like objects. Parallel lines extend from the mushroom shapes to the center of the dancers' heads.<a href="#fn2" class="footnote-ref" id="fnref2"><sup>2</sup></a> Six thousand year-old <a href="pictographs" class="uri" title="wikilink">pictographs</a> discovered near the Spanish town of <a href="Villar_del_Humo" title="wikilink">Villar del Humo</a> illustrate several mushrooms that have been tentatively identified as <em><a href="Psilocybe_hispanica" title="wikilink">Psilocybe hispanica</a></em>, a hallucinogenic species native to the area.<a href="#fn3" class="footnote-ref" id="fnref3"><sup>3</sup></a> Archaeological <a href="Artifact_(archaeology)" title="wikilink">artifacts</a> from Mexico, as well as the so-called Mayan &quot;mushroom stones&quot; of Guatemala have similarly been interpreted by some scholars as evidence for ritual and ceremonial usage of psychoactive mushrooms in the <a href="Maya_civilization" title="wikilink">Mayan</a> and <a href="Aztec" class="uri" title="wikilink">Aztec</a> cultures of Mesoamerica.<a href="#fn4" class="footnote-ref" id="fnref4"><sup>4</sup></a> In <a href="Nahuatl" class="uri" title="wikilink">Nahuatl</a>, the language of the Aztecs, the mushrooms were called <em>teonan&lt;U+00E1&gt;catl</em>, or &quot;God's flesh&quot;. Following the arrival of Spanish explorers to the <a href="New_World" title="wikilink">New World</a> in the 16th century, chroniclers reported the use of mushrooms by the natives for ceremonial and religious purposes. According to the <a href="Dominican_Order" title="wikilink">Dominican</a> friar <a href="Diego_Dur&lt;U+00E1&gt;n" title="wikilink">Diego Dur&lt;U+00E1&gt;n</a> in <em>The History of the Indies of New Spain</em> (published c. 1581), mushrooms were eaten in festivities conducted on the occasion of the accession to the throne of Aztec emperor <a href="Moctezuma_II" title="wikilink">Moctezuma II</a> in 1502. The <a href="Franciscan" class="uri" title="wikilink">Franciscan</a> friar <a href="Bernardino_de_Sahag&lt;U+00FA&gt;n" title="wikilink">Bernardino de Sahag&lt;U+00FA&gt;n</a> wrote of witnessing mushroom usage in his <a href="Florentine_Codex" title="wikilink">Florentine Codex</a> (published 1545&lt;U+2013&gt;1590),<a href="#fn5" class="footnote-ref" id="fnref5"><sup>5</sup></a> and described how some merchants would celebrate upon returning from a successful business trip by consuming mushrooms to evoke revelatory visions.<a href="#fn6" class="footnote-ref" id="fnref6"><sup>6</sup></a> After the <a href="Spanish_conquest_of_the_Aztec_Empire" title="wikilink">defeat of the Aztecs</a>, the Spanish forbade traditional religious practices and rituals that they considered &quot;pagan idolatry&quot;, including ceremonial mushroom use. For the next four centuries, the Indians of Mesoamerica hid their use of entheogens from the Spanish conquerors.<a href="#fn7" class="footnote-ref" id="fnref7"><sup>7</sup></a></p>
<p>Although several psychedelic mushrooms are found in Europe, there is little documented usage of these species in <a href="Old_World" title="wikilink">Old World</a> history. The few existing historical accounts about psilocybin mushrooms typically lack sufficient information to allow species identification, and usually refer to the nature of their effects. For example, Flemish botanist <a href="Carolus_Clusius" title="wikilink">Carolus Clusius</a> (1526&lt;U+2013&gt;1609) described the <em>bolond gomba</em> (crazy mushroom), used in rural Hungary to prepare love potions. English botanist <a href="John_Parkinson_(botanist)" title="wikilink">John Parkinson</a> included details about a &quot;foolish mushroom&quot; in his 1640 <a href="herbal" class="uri" title="wikilink">herbal</a> <em>Theatricum Botanicum</em>.<a href="#fn8" class="footnote-ref" id="fnref8"><sup>8</sup></a> The first reliably documented report of intoxication with <em>Psilocybe semilanceata</em>&lt;U+2014&gt;European's most common and widespread psychedelic mushroom&lt;U+2014&gt;involved a British family in 1799, who prepared a meal with mushrooms they had picked in London's <a href="Green_Park" title="wikilink">Green Park</a>.<a href="#fn9" class="footnote-ref" id="fnref9"><sup>9</sup></a></p>
<h3 id="modern">Modern</h3>
<p>American banker and amateur <a href="ethnomycologist" class="uri" title="wikilink">ethnomycologist</a> <a href="R._Gordon_Wasson" title="wikilink">R. Gordon Wasson</a> and his wife Valentina studied the ritual use of psychoactive mushrooms by the native population in the <a href="Mazatec_people" title="wikilink">Mazatec</a> village <a href="Huautla_de_Jim&lt;U+00E9&gt;nez" title="wikilink">Huautla de Jim&lt;U+00E9&gt;nez</a>. In 1957, Wasson wrote an article for the popular American weekly magazine <em><a href="Life_(magazine)" title="wikilink">Life</a></em> (&quot;Seeking the Magic Mushroom&quot;), in which he described the psychedelic visions that he experienced during these rituals.<a href="#fn10" class="footnote-ref" id="fnref10"><sup>10</sup></a> Later the same year they were accompanied on a followup expedition by French mycologist <a href="Roger_Heim" title="wikilink">Roger Heim</a>, who identified several of the mushrooms as <em>Psilocybe</em> species.<a href="#fn11" class="footnote-ref" id="fnref11"><sup>11</sup></a> Heim cultivated the mushrooms in France, and sent samples for analysis to <a href="Albert_Hofmann" title="wikilink">Albert Hofmann</a>, a chemist employed by the Swiss multinational pharmaceutical company <a href="Sandoz" class="uri" title="wikilink">Sandoz</a> (now Novartis). Hofmann, who had in 1938 created <a href="LSD" class="uri" title="wikilink">LSD</a>, led a research group that isolated and identified the psychoactive compounds from <em><a href="Psilocybe_mexicana" title="wikilink">Psilocybe mexicana</a></em>.<a href="#fn12" class="footnote-ref" id="fnref12"><sup>12</sup></a><a href="#fn13" class="footnote-ref" id="fnref13"><sup>13</sup></a> Hofmann was aided in the discovery process by his willingness to ingest mushroom <a href="Liquid-liquid_extraction" title="wikilink">extracts</a> to help verify the presence of the active compounds.<a href="#fn14" class="footnote-ref" id="fnref14"><sup>14</sup></a> He and his colleagues later <a href="chemical_synthesis" title="wikilink">synthesized</a> a number of compounds chemically related to the naturally occurring psilocybin, to see how <a href="chemical_structure" title="wikilink">structural</a> changes would affect psychoactivity. The new molecules differed from psilocybin in the position of the <a href="phosphoryl" class="uri" title="wikilink">phosphoryl</a> or <a href="hydroxyl" class="uri" title="wikilink">hydroxyl</a> group at the top of the <a href="indole_ring" title="wikilink">indole ring</a>, and in the numbers of <a href="methyl" class="uri" title="wikilink">methyl</a> groups (CH<sub>3</sub>) and other additional <a href="carbon_chain" title="wikilink">carbon chains</a>.<a href="#fn15" class="footnote-ref" id="fnref15"><sup>15</sup></a> <img src="Albert_Hofmann_Oct_1993.jpg" title="fig:Albert Hofmann (shown here in 1993) purified psilocybin and psilocin from Psilocybe mexicana in the late 1950s." alt="Albert Hofmann (shown here in 1993) purified psilocybin and psilocin from Psilocybe mexicana in the late 1950s." /> Two diethyl <a href="structural_analog" title="wikilink">analogs</a> (containing two <a href="Ethyl_group" title="wikilink">ethyl</a> groups in place of the two <a href="methyl" class="uri" title="wikilink">methyl</a> groups) of psilocybin and psilocin were synthesized by Hofmann: <a href="Ethocybin" title="wikilink">4-phosphoryloxy-N,N-diethyltryptamine</a>, called CEY-19, and <a href="4-HO-DET" title="wikilink">4-hydroxy-N,N-diethyltryptamine</a>, called CZ-74. Because their physiological effects last only about three and a half hours (about half as long as psilocybin), they proved more manageable in European clinics using &quot;<a href="Psychedelic_therapy#Psycholytic_therapy" title="wikilink">psycholytic therapy</a>&quot;&lt;U+2014&gt;a form of <a href="psychotherapy" class="uri" title="wikilink">psychotherapy</a> involving the controlled use of psychedelic drugs.<a href="#fn16" class="footnote-ref" id="fnref16"><sup>16</sup></a> Sandoz marketed and sold pure psilocybin under the name Indocybin to physicians and clinicians worldwide.<a href="#fn17" class="footnote-ref" id="fnref17"><sup>17</sup></a> There were no reports of serious complications when psilocybin was used in this way.<a href="#fn18" class="footnote-ref" id="fnref18"><sup>18</sup></a></p>
<p>In the early 1960s, <a href="Harvard_University" title="wikilink">Harvard University</a> became a testing ground for psilocybin, through the efforts of <a href="Timothy_Leary" title="wikilink">Timothy Leary</a> and his associates <a href="Ralph_Metzner" title="wikilink">Ralph Metzner</a> and Richard Alpert (who later changed his name to <a href="Ram_Dass" title="wikilink">Ram Dass</a>). Leary obtained synthesized psilocybin from Hofmann through Sandoz pharmaceutical. Some studies in the early 1960s, such as the <a href="Concord_Prison_Experiment" title="wikilink">Concord Prison Experiment</a>, initially suggested promising results using psilocybin in <a href="clinical_psychiatry" title="wikilink">clinical psychiatry</a>.<a href="#fn19" class="footnote-ref" id="fnref19"><sup>19</sup></a><a href="#fn20" class="footnote-ref" id="fnref20"><sup>20</sup></a> However, according to a 2008 review of safety guidelines in human hallucinogenic research, Leary and Alpert's well-publicized termination from Harvard and later advocacy of hallucinogen use &quot;further undermined an objective scientific approach to studying these compounds&quot;.<a href="#fn21" class="footnote-ref" id="fnref21"><sup>21</sup></a> In response to concerns about the increase in unauthorized use of psychedelic drugs by the general public, psilocybin and other hallucinogenic drugs suffered negative press and faced increasingly restrictive laws. In the United States, laws were passed in 1966 that prohibited the production, trade, or ingestion of hallucinogenic drugs; Sandoz stopped producing LSD and psilocybin the same year.<a href="#fn22" class="footnote-ref" id="fnref22"><sup>22</sup></a> Further backlash against LSD usage swept psilocybin along with it into the <a href="Schedule_I_(US)#Schedule_I_drugs" title="wikilink">Schedule I category</a> of illicit drugs in 1970. Subsequent restrictions on the use of these drugs in human research made <a href="research_funding" title="wikilink">funding</a> for such projects difficult to obtain, and scientists who worked with psychedelic drugs faced being &quot;professionally marginalized&quot;.<a href="#fn23" class="footnote-ref" id="fnref23"><sup>23</sup></a> <img src="Golden_teacher_kookoskuidussa_3.jpg" title="fig:The increasing availability of information on growing techniques made it possible for amateurs to grow psilocybin mushrooms (Psilocybe cubensis pictured) without access to laboratory equipment." alt="The increasing availability of information on growing techniques made it possible for amateurs to grow psilocybin mushrooms (Psilocybe cubensis pictured) without access to laboratory equipment." /> Despite the legal restrictions on psilocybin use, the 1970s witnessed the emergence of psilocybin as the &quot;entheogen of choice&quot;.<a href="#fn24" class="footnote-ref" id="fnref24"><sup>24</sup></a> This was due in large part to a wide dissemination of information on the topic, which included works such as those by author <a href="Carlos_Castaneda" title="wikilink">Carlos Castaneda</a>, and several books that taught the technique of growing psilocybin mushrooms. One of the most popular of this latter group was published in 1976 under the pseudonyms O.T. Oss and O.N. Oeric by Jeremy Bigwood, <a href="Dennis_Jon_McKenna" title="wikilink">Dennis J. McKenna</a>, K. Harrison McKenna, and <a href="Terence_McKenna" title="wikilink">Terence McKenna</a>, entitled <em>Psilocybin: Magic Mushroom Grower's Guide</em>. Over 100,000 copies were sold by 1981.<a href="#fn25" class="footnote-ref" id="fnref25"><sup>25</sup></a> As ethnobiologist <a href="Jonathan_Ott" title="wikilink">Jonathan Ott</a> explains, &quot;These authors adapted San Antonio's technique (for producing edible mushrooms by casing <a href="mycelium" title="wikilink">mycelial</a> cultures on a rye grain substrate; San Antonio 1971) to the production of <em>Psilocybe [Stropharia] cubensis</em>. The new technique involved the use of ordinary kitchen implements, and for the first time the layperson was able to produce a potent entheogen in his own home, without access to sophisticated technology, equipment or chemical supplies.&quot;<a href="#fn26" class="footnote-ref" id="fnref26"><sup>26</sup></a></p>
<p>Because of a lack of clarity about laws about psilocybin mushrooms, retailers in the late 1990s and early 2000s (decade) commercialized and marketed them in <a href="smartshop" title="wikilink">smartshops</a> in the Netherlands and the UK, and on the internet. Several websites emerged that have contributed to the accessibility of information on description, use, effects and exchange of experiences among users. Since 2001, six <a href="European_Union" title="wikilink">EU</a> countries have tightened their legislation on psilocybin mushrooms in response to concerns about their prevalence and increasing usage.<a href="#fn27" class="footnote-ref" id="fnref27"><sup>27</sup></a> In the 1990s, hallucinogens and their effects on human consciousness were again the subject of scientific study, particularly in Europe. Advances in <a href="neuropharmacology" class="uri" title="wikilink">neuropharmacology</a> and <a href="neuropsychology" class="uri" title="wikilink">neuropsychology</a>, and the availability of <a href="Neuroimaging" title="wikilink">brain imaging</a> techniques have provided impetus for using drugs like psilocybin to probe the &quot;neural underpinnings of psychotic symptom formation including ego disorders and hallucinations&quot;.<a href="#fn28" class="footnote-ref" id="fnref28"><sup>28</sup></a> Recent studies in the United States have attracted attention from the popular press and thrust psilocybin back into the limelight.<a href="#fn29" class="footnote-ref" id="fnref29"><sup>29</sup></a><a href="#fn30" class="footnote-ref" id="fnref30"><sup>30</sup></a></p>
<h2 id="occurrence">Occurrence</h2>

<p>Psilocybin is present in varying concentrations in over 200 species of <a href="Basidiomycota" class="uri" title="wikilink">Basidiomycota</a> mushrooms. In a 2000 review on the worldwide distribution of hallucinogenic mushrooms, <a href="Gast&lt;U+00F3&gt;n_Guzm&lt;U+00E1&gt;n" title="wikilink">Gast&lt;U+00F3&gt;n Guzm&lt;U+00E1&gt;n</a> and colleagues considered these to be distributed amongst the following <a href="genus" title="wikilink">genera</a>: <em><a href="Psilocybe" class="uri" title="wikilink">Psilocybe</a></em> (116 species), <em><a href="Gymnopilus" class="uri" title="wikilink">Gymnopilus</a></em> (14), <em><a href="Panaeolus" class="uri" title="wikilink">Panaeolus</a></em> (13), <em><a href="Copelandia" class="uri" title="wikilink">Copelandia</a></em> (12), <em><a href="Hypholoma" class="uri" title="wikilink">Hypholoma</a></em> (6), <em><a href="Pluteus" class="uri" title="wikilink">Pluteus</a></em> (6) <em><a href="Inocybe" class="uri" title="wikilink">Inocybe</a></em> (6), <em><a href="Conocybe" class="uri" title="wikilink">Conocybe</a></em> (4), <em><a href="Panaeolina" class="uri" title="wikilink">Panaeolina</a></em> (4), <em><a href="Gerronema" class="uri" title="wikilink">Gerronema</a></em> (2) and <em><a href="Agrocybe" class="uri" title="wikilink">Agrocybe</a></em>, <em><a href="Galerina" class="uri" title="wikilink">Galerina</a></em> and <em><a href="Mycena" class="uri" title="wikilink">Mycena</a></em> (1 species each).<a href="#fn31" class="footnote-ref" id="fnref31"><sup>31</sup></a> Guzm&lt;U+00E1&gt;n increased his estimate of the number of psilocybin-containing <em>Psilocybe</em> to 144 species in a 2005 review. The majority of these are found in Mexico (53 species), with the remainder distributed in the US and Canada (22), Europe (16), Asia (15), Africa (4), and Australia and associated islands (19).<a href="#fn32" class="footnote-ref" id="fnref32"><sup>32</sup></a> In general, psilocybin-containing species are dark-spored, <a href="lamella_(mycology)" title="wikilink">gilled</a> mushrooms that grow in meadows and woods of the <a href="subtropic" title="wikilink">subtropics</a> and <a href="tropics" class="uri" title="wikilink">tropics</a>, usually in soils rich in <a href="humus" class="uri" title="wikilink">humus</a> and plant debris.<a href="#fn33" class="footnote-ref" id="fnref33"><sup>33</sup></a> Psilocybin mushrooms occur on all continents, but the majority of species are found in <a href="Tropical_and_subtropical_moist_broadleaf_forests" title="wikilink">subtropical humid forests</a>.<a href="#fn34" class="footnote-ref" id="fnref34"><sup>34</sup></a> <em>Psilocybe</em> species commonly found in the tropics include <em><a href="Psilocybe_cubensis" title="wikilink">P. cubensis</a></em> and <em><a href="Psilocybe_subcubensis" title="wikilink">P. subcubensis</a></em>. <em><a href="Psilocybe_semilanceata" title="wikilink">P. semilanceata</a></em>&lt;U+2014&gt;considered by Guzm&lt;U+00E1&gt;n to be the world's most widely distributed psilocybin mushroom<a href="#fn35" class="footnote-ref" id="fnref35"><sup>35</sup></a>&lt;U+2014&gt;is found in Europe, North America, Asia, South America, Australia and New Zealand, but is entirely absent from Mexico.<a href="#fn36" class="footnote-ref" id="fnref36"><sup>36</sup></a> Although the presence or absence of psilocybin is not of much use as a <a href="chemotaxonomy" title="wikilink">chemotaxonomical</a> marker at the <a href="family_(biology)" title="wikilink">familial</a> level or higher, it is used to classify <a href="taxon" title="wikilink">taxa</a> of lower taxonomic groups.<a href="#fn37" class="footnote-ref" id="fnref37"><sup>37</sup></a></p>
<table>
<thead>
<tr class="header">
<th><p>Species</p></th>
<th><p>% psilocybin |- ! scope=&quot;row&quot;</p></th>
<th><p><em><a href="Psilocybe_azurescens" title="wikilink">P. azurescens</a></em></p></th>
<th><center>
<p>1.78</p>
</center>
<p>|- ! scope=&quot;row&quot;</p></th>
<th><p><em><a href="Psilocybe_serbica" title="wikilink">P. serbica</a></em></p></th>
<th><center>
<p>1.34</p>
</center>
<p>|- ! scope=&quot;row&quot;</p></th>
<th><p><em><a href="Psilocybe_semilanceata" title="wikilink">P. semilanceata</a></em></p></th>
<th><center>
<p>0.98</p>
</center>
<p>|- ! scope=&quot;row&quot;</p></th>
<th><p><em><a href="Psilocybe_baeocystis" title="wikilink">P. baeocystis</a></em></p></th>
<th><center>
<p>0.85</p>
</center>
<p>|- ! scope=&quot;row&quot;</p></th>
<th><p><em><a href="Psilocybe_cyanescens" title="wikilink">P. cyanescens</a></em></p></th>
<th><center>
<p>0.85</p>
</center>
<p>|- ! scope=&quot;row&quot;</p></th>
<th><p><em><a href="Psilocybe_tampanensis" title="wikilink">P. tampanensis</a></em></p></th>
<th><center>
<p>0.68</p>
</center>
<p>|- ! scope=&quot;row&quot;</p></th>
<th><p><em><a href="Psilocybe_cubensis" title="wikilink">P. cubensis</a></em></p></th>
<th><center>
<p>0.63</p>
</center>
<p>|- ! scope=&quot;row&quot;</p></th>
<th><p><em><a href="Psilocybe_weilii" title="wikilink">P. weilii</a></em></p></th>
<th><center>
<p>0.61</p>
</center>
<p>|- ! scope=&quot;row&quot;</p></th>
<th><p><em><a href="Psilocybe_hoogshagenii" title="wikilink">P. hoogshagenii</a></em></p></th>
<th><center>
<p>0.60</p>
</center>
<p>|- ! scope=&quot;row&quot;</p></th>
<th><p><em><a href="Psilocybe_stuntzii" title="wikilink">P. stuntzii</a></em></p></th>
<th><center>
<p>0.36</p>
</center>
<p>|- ! scope=&quot;row&quot;</p></th>
<th><p><em><a href="Psilocybe_cyanofibrillosa" title="wikilink">P. cyanofibrillosa</a></em></p></th>
<th><center>
<p>0.21</p>
</center>
<p>|- ! scope=&quot;row&quot;</p></th>
<th><p><em><a href="Psilocybe_liniformans" title="wikilink">P. liniformans</a></em></p></th>
<th><center>
<p>0.16</p>
</center></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Maximum reported psilocybin concentrations (% dry weight) in 12 <em>Psilocybe</em> species<a href="#fn38" class="footnote-ref" id="fnref38"><sup>38</sup></a></p></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p>Mushroom <a href="pileus_(mycology)" title="wikilink">caps</a> tend to contain more of the psychoactive compounds than the <a href="stipe_(mycology)" title="wikilink">stems</a>. The <a href="spore" title="wikilink">spores</a> of these mushrooms do not contain psilocybin or psilocin.<a href="#fn39" class="footnote-ref" id="fnref39"><sup>39</sup></a><a href="#fn40" class="footnote-ref" id="fnref40"><sup>40</sup></a><a href="#fn41" class="footnote-ref" id="fnref41"><sup>41</sup></a> The total <a href="potency_(pharmacology)" title="wikilink">potency</a> varies greatly between species and even between specimens of one species collected from the same fungus.<a href="#fn42" class="footnote-ref" id="fnref42"><sup>42</sup></a> Because most psilocybin biosynthesis occurs early in the formation of <a href="basidiocarp" title="wikilink">fruit bodies</a> or <a href="sclerotium" title="wikilink">sclerotia</a>, younger, smaller mushrooms tend to have a higher concentration of the drug than larger, mature mushrooms.<a href="#fn43" class="footnote-ref" id="fnref43"><sup>43</sup></a> In general, the psilocybin content of mushrooms is quite variable (ranging from almost nothing to 1.5% of the <a href="dry_matter" title="wikilink">dry weight</a>)<a href="#fn44" class="footnote-ref" id="fnref44"><sup>44</sup></a> and depends on species, growth and drying conditions, and mushroom size.<a href="#fn45" class="footnote-ref" id="fnref45"><sup>45</sup></a> Cultivated mushrooms have less variability in psilocybin content than wild mushrooms.<a href="#fn46" class="footnote-ref" id="fnref46"><sup>46</sup></a> The drug is more stable in dried than fresh mushrooms; dried mushrooms retain their potency for months or even years,<a href="#fn47" class="footnote-ref" id="fnref47"><sup>47</sup></a> while mushrooms stored fresh for four weeks contain only traces of the original psilocybin.<a href="#fn48" class="footnote-ref" id="fnref48"><sup>48</sup></a> The psilocybin contents of dried <a href="herbarium" class="uri" title="wikilink">herbarium</a> specimens of <em>Psilocybe semilanceata</em> in one study were shown to decrease with the increasing age of the sample: collections dated 11, 33, or 118 years old contained 0.84%, 0.67%, and 0.014% (all dry weight), respectively.<a href="#fn49" class="footnote-ref" id="fnref49"><sup>49</sup></a> Mature <a href="mycelia" class="uri" title="wikilink">mycelia</a> contain some psilocybin, while young mycelia (recently <a href="germination" title="wikilink">germinated</a> from spores) lack appreciable amounts.<a href="#fn50" class="footnote-ref" id="fnref50"><sup>50</sup></a> Many species of mushrooms containing psilocybin also contain lesser amounts of the analog compounds <a href="baeocystin" class="uri" title="wikilink">baeocystin</a> and <a href="norbaeocystin" class="uri" title="wikilink">norbaeocystin</a>,<a href="#fn51" class="footnote-ref" id="fnref51"><sup>51</sup></a> chemicals thought to be biogenic <a href="precursor_(chemistry)" title="wikilink">precursors</a>.<a href="#fn52" class="footnote-ref" id="fnref52"><sup>52</sup></a> Most species of psilocybin-containing mushrooms bruise blue when handled or damaged due to the <a href="Redox" title="wikilink">oxidization</a> of phenolic compounds. This reaction, however, is not a definitive method of identification or determining a mushroom's potency.<a href="#fn53" class="footnote-ref" id="fnref53"><sup>53</sup></a><a href="#fn54" class="footnote-ref" id="fnref54"><sup>54</sup></a> {{-}}</p>
<h2 id="chemistry">Chemistry</h2>
<p>Psilocybin (<em>O</em>-phosphoryl-4-hydroxy-<em>N,N</em>-<a href="dimethyltryptamine" class="uri" title="wikilink">dimethyltryptamine</a> or 4-PO-DMT) is a <a href="prodrug" class="uri" title="wikilink">prodrug</a> that is converted into the <a href="Pharmacology" title="wikilink">pharmacologically</a> active compound <a href="psilocin" class="uri" title="wikilink">psilocin</a> in the body by a <a href="dephosphorylation" class="uri" title="wikilink">dephosphorylation</a> reaction. This <a href="chemical_reaction" title="wikilink">chemical reaction</a> takes place under strongly <a href="acidic" class="uri" title="wikilink">acidic</a> conditions, or under <a href="physiological_condition" title="wikilink">physiological conditions</a> in the body, through the action of <a href="enzyme" title="wikilink">enzymes</a> called <a href="phosphatase" title="wikilink">phosphatases</a>.<a href="#fn55" class="footnote-ref" id="fnref55"><sup>55</sup></a></p>
<p>Psilocybin is a <a href="tryptamine" class="uri" title="wikilink">tryptamine</a> compound with a <a href="chemical_structure" title="wikilink">chemical structure</a> containing an <a href="indole" class="uri" title="wikilink">indole</a> ring linked to an <a href="ethylamine" class="uri" title="wikilink">ethylamine</a> <a href="substituent" class="uri" title="wikilink">substituent</a>. It is chemically related to the <a href="amino_acid" title="wikilink">amino acid</a> <a href="tryptophan" class="uri" title="wikilink">tryptophan</a>, and is structurally similar to the <a href="neurotransmitter" class="uri" title="wikilink">neurotransmitter</a> <a href="serotonin" class="uri" title="wikilink">serotonin</a>. Psilocybin is a member of the general class of tryptophan-based compounds that originally functioned as <a href="antioxidant" title="wikilink">antioxidants</a> in earlier life forms before assuming more complex functions in multicellular organisms, including humans.<a href="#fn56" class="footnote-ref" id="fnref56"><sup>56</sup></a> Other related indole-containing psychedelic compounds include <a href="N,N-dimethyltryptamine" title="wikilink">dimethyltryptamine</a>, found in many plant species and in trace amounts in some mammals, and <a href="bufotenine" class="uri" title="wikilink">bufotenine</a>, found in the skin of <a href="psychoactive_toads" title="wikilink">psychoactive toads</a>.<a href="#fn57" class="footnote-ref" id="fnref57"><sup>57</sup></a> Biosynthetically, the biochemical transformation from tryptophan to psilocybin involves several enzyme reactions: <a href="decarboxylation" class="uri" title="wikilink">decarboxylation</a>, <a href="methylation" class="uri" title="wikilink">methylation</a> at the N<sup>9</sup> position, 4-<a href="hydroxylation" class="uri" title="wikilink">hydroxylation</a>, and <em>O</em>-<a href="phosphorylation" class="uri" title="wikilink">phosphorylation</a>. <a href="Isotopic_labeling" title="wikilink">Isotopic labeling</a> experiments suggest that tryptophan decarboxylation is the initial biosynthetic step and that <em>O</em>-phosphorylation is the final step.<a href="#fn58" class="footnote-ref" id="fnref58"><sup>58</sup></a><a href="#fn59" class="footnote-ref" id="fnref59"><sup>59</sup></a> The precise sequence of the intermediate enzymatic steps is not known with certainty, and the biosynthetic pathway may differ between species.<a href="#fn60" class="footnote-ref" id="fnref60"><sup>60</sup></a> <img src="Biosynthesis_of_psilocybin.svg" title="fig:A possible biosynthetic route to psilocybin. Although the order of the first (decarboxylation) and last (phosphorylation) steps are known with some certainty, the sequence of the two intermediate steps is speculative." alt="A possible biosynthetic route to psilocybin. Although the order of the first (decarboxylation) and last (phosphorylation) steps are known with some certainty, the sequence of the two intermediate steps is speculative." width="800" /> Psilocybin is a <a href="zwitterion" title="wikilink">zwitterionic</a> <a href="alkaloid" class="uri" title="wikilink">alkaloid</a> that is <a href="solubility" title="wikilink">soluble</a> in water, <a href="methanol" class="uri" title="wikilink">methanol</a> and <a href="Ethanol_(data_page)#Properties_of_aqueous_ethanol_solutions" title="wikilink">aqueous ethanol</a>, but insoluble in <a href="organic_solvent" title="wikilink">organic solvents</a> like <a href="chloroform" class="uri" title="wikilink">chloroform</a> and <a href="petroleum_ether" title="wikilink">petroleum ether</a>.<a href="#fn61" class="footnote-ref" id="fnref61"><sup>61</sup></a> Exposure to light is detrimental to the stability of <a href="aqueous_solution" title="wikilink">aqueous solutions</a> of psilocybin, and will cause it to rapidly oxidize&lt;U+2014&gt;an important consideration when using it as an analytical <a href="standard_solution" title="wikilink">standard</a>.<a href="#fn62" class="footnote-ref" id="fnref62"><sup>62</sup></a> Osamu Shirota and colleagues reported a method for the large-scale synthesis of psilocybin without <a href="chromatography" title="wikilink">chromatographic</a> purification in 2003.<a href="#fn63" class="footnote-ref" id="fnref63"><sup>63</sup></a> Starting with 4-hydroxyindole, they generated psilocybin from psilocin in 85% <a href="yield_(chemistry)" title="wikilink">yield</a>, a marked improvement over yields reported from previous syntheses.<a href="#fn64" class="footnote-ref" id="fnref64"><sup>64</sup></a><a href="#fn65" class="footnote-ref" id="fnref65"><sup>65</sup></a><a href="#fn66" class="footnote-ref" id="fnref66"><sup>66</sup></a> Purified psilocybin is a white, needle-like crystalline powder<a href="#fn67" class="footnote-ref" id="fnref67"><sup>67</sup></a> with a <a href="melting_point" title="wikilink">melting point</a> between ,<a href="#fn68" class="footnote-ref" id="fnref68"><sup>68</sup></a> and a slightly <a href="ammonia" class="uri" title="wikilink">ammonia</a>-like taste.<a href="#fn69" class="footnote-ref" id="fnref69"><sup>69</sup></a></p>
<h3 id="analytical-methods">Analytical methods</h3>
<p>Several relatively simple <a href="chemical_test" title="wikilink">chemical tests</a>&lt;U+2014&gt;commercially available as <a href="Pill_testing#Reagent_Testing_Kits" title="wikilink">reagent testing kits</a>&lt;U+2014&gt;can be used to assess the presence of psilocybin in <a href="extract" title="wikilink">extracts</a> prepared from mushrooms. The drug reacts in the <a href="Marquis_reagent" title="wikilink">Marquis test</a> to produce a yellow color, and a green color in the <a href="Pill_testing#Reagent_Testing_Kits" title="wikilink">Mandelin test</a>.<a href="#fn70" class="footnote-ref" id="fnref70"><sup>70</sup></a> Neither of these tests, however, is specific for psilocybin; for example, the Marquis test will react with many classes of controlled drugs, such as those containing <a href="Amine#Classes_of_amines" title="wikilink">primary amino</a> groups and unsubstituted <a href="benzene_ring" title="wikilink">benzene rings</a>, including <a href="amphetamine" class="uri" title="wikilink">amphetamine</a> and <a href="methamphetamine" class="uri" title="wikilink">methamphetamine</a>.<a href="#fn71" class="footnote-ref" id="fnref71"><sup>71</sup></a> <a href="Ehrlich&#39;s_reagent" title="wikilink">Ehrlich's reagent</a> and <a href="DMACA_reagent" title="wikilink">DMACA reagent</a> are used as chemical sprays to detect the drug after <a href="thin_layer_chromatography" title="wikilink">thin layer chromatography</a>.<a href="#fn72" class="footnote-ref" id="fnref72"><sup>72</sup></a> Many modern techniques of <a href="analytical_chemistry" title="wikilink">analytical chemistry</a> have been used to quantify psilocybin levels in mushroom samples. Although the earliest methods commonly used <a href="gas_chromatography" title="wikilink">gas chromatography</a>, the high temperature required to <a href="Volatility_(chemistry)" title="wikilink">vaporize</a> the psilocybin sample prior to analysis causes it to spontaneously lose its phosphoryl group and become psilocin&lt;U+2014&gt;making it difficult to chemically discriminate between the two drugs. In <a href="forensic_toxicology" title="wikilink">forensic toxicology</a>, techniques involving <a href="Gas_chromatography-mass_spectrometry" title="wikilink">gas chromatography coupled to mass spectrometry</a> (GC&lt;U+2013&gt;MS) are the most widely used due to their high sensitivity and ability to separate compounds in complex biological mixtures.<a href="#fn73" class="footnote-ref" id="fnref73"><sup>73</sup></a> These techniques include <a href="ion_mobility_spectrometry" title="wikilink">ion mobility spectrometry</a>,<a href="#fn74" class="footnote-ref" id="fnref74"><sup>74</sup></a> <a href="capillary_zone_electrophoresis" title="wikilink">capillary zone electrophoresis</a>,<a href="#fn75" class="footnote-ref" id="fnref75"><sup>75</sup></a> <a href="Ultraviolet&lt;U+2013&gt;visible_spectroscopy" title="wikilink">ultraviolet spectroscopy</a>,<a href="#fn76" class="footnote-ref" id="fnref76"><sup>76</sup></a> and <a href="infrared_spectroscopy" title="wikilink">infrared spectroscopy</a>.<a href="#fn77" class="footnote-ref" id="fnref77"><sup>77</sup></a> <a href="High_performance_liquid_chromatography" title="wikilink">High performance liquid chromatography</a> (HPLC) is used with ultraviolet,<a href="#fn78" class="footnote-ref" id="fnref78"><sup>78</sup></a> <a href="Fluorescence_spectroscopy" title="wikilink">fluorescence</a>,<a href="#fn79" class="footnote-ref" id="fnref79"><sup>79</sup></a> <a href="Electrochemistry" title="wikilink">electrochemical</a>,<a href="#fn80" class="footnote-ref" id="fnref80"><sup>80</sup></a> and <a href="Electrospray_ionization" title="wikilink">electrospray</a> mass spectrometric detection methods.<a href="#fn81" class="footnote-ref" id="fnref81"><sup>81</sup></a></p>
<p>Various <a href="chromatography" title="wikilink">chromatographic</a> methods have been developed to detect psilocin in <a href="Bodily_fluid" title="wikilink">body fluids</a>: the rapid emergency drug identification system (REMEDi HS), a <a href="drug_test" title="wikilink">drug screening</a> method based on HPLC;<a href="#fn82" class="footnote-ref" id="fnref82"><sup>82</sup></a> HPLC with electrochemical detection;<a href="#fn83" class="footnote-ref" id="fnref83"><sup>83</sup></a><a href="#fn84" class="footnote-ref" id="fnref84"><sup>84</sup></a> GC&lt;U+2013&gt;MS;<a href="#fn85" class="footnote-ref" id="fnref85"><sup>85</sup></a><a href="#fn86" class="footnote-ref" id="fnref86"><sup>86</sup></a> and <a href="Liquid_chromatography&lt;U+2013&gt;mass_spectrometry" title="wikilink">liquid chromatography coupled to mass spectrometry</a>.<a href="#fn87" class="footnote-ref" id="fnref87"><sup>87</sup></a> Although the determination of psilocin levels in urine can be performed without sample clean-up (i.e., removing potential contaminants that make it difficult to accurately assess concentration), the analysis in <a href="blood_plasma" title="wikilink">plasma</a> or <a href="blood_serum" title="wikilink">serum</a> requires a preliminary <a href="Liquid-liquid_extraction" title="wikilink">extraction</a>, followed by <a href="derivatization" class="uri" title="wikilink">derivatization</a> of the extracts in the case of GC&lt;U+2013&gt;MS. A specific <a href="immunoassay" class="uri" title="wikilink">immunoassay</a> has also been developed to detect psilocin in whole blood samples.<a href="#fn88" class="footnote-ref" id="fnref88"><sup>88</sup></a> A 2009 publication reported using HPLC to quickly separate forensically important illicit drugs including psilocybin and psilocin, which were identifiable within about half a minute of analysis time.<a href="#fn89" class="footnote-ref" id="fnref89"><sup>89</sup></a> These analytical techniques to determine psilocybin concentrations in body fluids are, however, not routinely available, and not typically used in <a href="Clinical_chemistry" title="wikilink">clinical</a> settings.<a href="#fn90" class="footnote-ref" id="fnref90"><sup>90</sup></a></p>
<h3 id="pharmacology">Pharmacology</h3>
<p><img src="Serotonin.svg" title="fig:The neurotransmitter serotonin is structurally similar to psilocybin." alt="The neurotransmitter serotonin is structurally similar to psilocybin." width="200" /> Psilocybin is rapidly dephosphorylated in the body to psilocin, which is a <a href="partial_agonist" title="wikilink">partial agonist</a> for several <a href="serotonin_receptor" title="wikilink">serotonergic receptors</a>. Psilocin has a high <a href="Affinity_(pharmacology)#Protein-ligand_binding" title="wikilink">affinity</a> for the <a href="5-HT2A_receptor" title="wikilink">5-HT<sub>2A</sub></a> serotonin receptor in the brain, where it mimics the effects of serotonin (5-hydroxytryptamine, or 5-HT). Psilocin binds less tightly to other serotonergic receptors <a href="5-HT1A_receptor" title="wikilink">5-HT<sub>1A</sub></a>, <a href="5-HT1D_receptor" title="wikilink">5-HT<sub>1D</sub></a>, and <a href="5-HT2C_receptor" title="wikilink">5-HT<sub>2C</sub></a>.<a href="#fn91" class="footnote-ref" id="fnref91"><sup>91</sup></a> Serotonin receptors are located in numerous parts of the brain, including the <a href="cerebral_cortex" title="wikilink">cerebral cortex</a>, and are involved in a wide range of functions, including regulation of <a href="mood_(psychology)" title="wikilink">mood</a> and <a href="motivation" class="uri" title="wikilink">motivation</a>.<a href="#fn92" class="footnote-ref" id="fnref92"><sup>92</sup></a> The <a href="psychotomimetic" class="uri" title="wikilink">psychotomimetic</a> (psychosis-mimicking) effects of psilocin can be blocked in a <a href="Dose_(biochemistry)#Effects_are_dose-dependent" title="wikilink">dose-dependent</a> fashion by the 5-HT<sub>2A</sub> <a href="receptor_antagonist" title="wikilink">antagonist</a> drugs <a href="ketanserin" class="uri" title="wikilink">ketanserin</a> and <a href="risperidone" class="uri" title="wikilink">risperidone</a>.<a href="#fn93" class="footnote-ref" id="fnref93"><sup>93</sup></a> Although the 5-HT<sub>2A</sub> receptor is responsible for most of the effects of psilocin, various lines of evidence have shown that interactions with non-5-HT<sub>2A</sub> receptors also contribute to the subjective and behavioral effects of the drug.<a href="#fn94" class="footnote-ref" id="fnref94"><sup>94</sup></a>{{#tag:ref|Subjective effects are &quot;feelings, perceptions, and moods personally experienced by an individual&quot;; they are often assessed using methods of <a href="self-report_study" title="wikilink">self-report</a>, including <a href="questionnaire" title="wikilink">questionnaires</a>. Behavioral effects, in contrast, can be observed directly.<a href="#fn95" class="footnote-ref" id="fnref95"><sup>95</sup></a>|group=nb}} For example, psilocin indirectly increases the concentration of the neurotransmitter <a href="dopamine" class="uri" title="wikilink">dopamine</a> in the <a href="basal_ganglia" title="wikilink">basal ganglia</a>, and some psychomimetic symptoms of psilocin are reduced by <a href="haloperidol" class="uri" title="wikilink">haloperidol</a>, an antagonist of <a href="dopamine_receptor_D2" title="wikilink">dopamine receptor D<sub>2</sub></a>. Taken together, these suggest that there may be an indirect <a href="dopaminergic" class="uri" title="wikilink">dopaminergic</a> contribution to psilocin's psychotic effects.<a href="#fn96" class="footnote-ref" id="fnref96"><sup>96</sup></a> In contrast to LSD, which binds to all <a href="dopamine_receptor" title="wikilink">dopamine receptor</a> subtypes, psilocybin and psilocin have no affinity for the dopamine receptors.<a href="#fn97" class="footnote-ref" id="fnref97"><sup>97</sup></a></p>
<p>The chemical structures of psilocybin and related <a href="structural_analog" title="wikilink">analogs</a> have been used in <a href="computational_biology" title="wikilink">computational biology</a> to help <a href="Molecular_modelling" title="wikilink">model</a> the <a href="Protein_structure_prediction" title="wikilink">structure</a>, function, and <a href="ligand_(biochemistry)" title="wikilink">ligand</a>-binding properties of the 5-HT<sub>2C</sub> <a href="G-protein-coupled_receptor" title="wikilink">G-protein-coupled receptor</a>.<a href="#fn98" class="footnote-ref" id="fnref98"><sup>98</sup></a><a href="#fn99" class="footnote-ref" id="fnref99"><sup>99</sup></a></p>
<h2 id="toxicity-and-harm-potential">Toxicity and harm potential</h2>
<p><img src="Drug_danger_and_dependence-no_title.svg" title="fig: Chart of dependence potential and effective dose/lethal dose ratio of several psychoactive drugs. Source:" alt=" Chart of dependence potential and effective dose/lethal dose ratio of several psychoactive drugs. Source:" width="480" /> The <a href="toxicity" class="uri" title="wikilink">toxicity</a> of psilocybin is low. In rats, the <a href="median_lethal_dose" title="wikilink">median lethal dose</a> (LD<sub>50</sub>) when administered orally is 280 milligrams per kilogram (mg/kg), approximately one and a half times that of <a href="caffeine" class="uri" title="wikilink">caffeine</a>. When administered <a href="intravenous_injection" title="wikilink">intravenously</a> in rabbits, psilocybin's LD<sub>50</sub> is approximately 12.5 mg/kg.<a href="#fn100" class="footnote-ref" id="fnref100"><sup>100</sup></a> Psilocybin comprises approximately 1% of the weight of <em>Psilocybe cubensis</em> mushrooms, and so nearly  of dried mushrooms, or  of fresh mushrooms, would be required for a  person to reach the 280 mg/kg LD<sub>50</sub> value of rats.<a href="#fn101" class="footnote-ref" id="fnref101"><sup>101</sup></a> Based on the results of animal studies, the <a href="lethal_dose" title="wikilink">lethal dose</a> of psilocybin has been extrapolated to be 6 grams, 1000 times greater than the <a href="effective_dose_(pharmacology)" title="wikilink">effective dose</a> of 6 milligrams.<a href="#fn102" class="footnote-ref" id="fnref102"><sup>102</sup></a> The <a href="Registry_of_Toxic_Effects_of_Chemical_Substances" title="wikilink">Registry of Toxic Effects of Chemical Substances</a> assigns psilocybin a relatively high <a href="therapeutic_index" title="wikilink">therapeutic index</a> of 641 (higher values correspond to a better safety profile); for comparison, the therapeutic indices of <a href="aspirin" class="uri" title="wikilink">aspirin</a> and <a href="nicotine" class="uri" title="wikilink">nicotine</a> are 199 and 21, respectively.<a href="#fn103" class="footnote-ref" id="fnref103"><sup>103</sup></a> The lethal dose from psilocybin toxicity alone is unknown at recreational or medicinal levels, and has rarely been documented&lt;U+2014&gt;as of 2011, only two cases attributed to overdosing on hallucinogenic mushrooms (without concurrent use of other drugs) have been reported in the scientific literature.<a href="#fn104" class="footnote-ref" id="fnref104"><sup>104</sup></a>{{#tag:ref|One of the reported fatalities, that of a 22-year old French man who died in 1993,<a href="#fn105" class="footnote-ref" id="fnref105"><sup>105</sup></a> was later challenged in the literature by Jochen Gartz and colleagues, who concluded &quot;the few reported data concerning the victim are insufficient to exclude other possible causes of the fatality&quot;.<a href="#fn106" class="footnote-ref" id="fnref106"><sup>106</sup></a>|group=nb}} Most of the comparatively few fatal incidents reported in the literature that are associated with psychedelic mushroom usage involve the simultaneous use of other drugs, especially <a href="ethanol" title="wikilink">alcohol</a>. Probably the most common cause of hospital admissions resulting from magic mushroom usage involve &quot;bad trips&quot; or <a href="panic_attack" title="wikilink">panic reactions</a>, in which affected individuals become extremely anxious, confused, agitated, or disoriented. Accidents, <a href="Self-harm" title="wikilink">self-injury</a>, or <a href="suicide" class="uri" title="wikilink">suicide</a> attempts can result from serious cases of acute <a href="psychosis" title="wikilink">psychotic episodes</a>.<a href="#fn107" class="footnote-ref" id="fnref107"><sup>107</sup></a></p>
<p>Repeated use of psilocybin does not lead to <a href="physical_dependence" title="wikilink">physical dependence</a>.<a href="#fn108" class="footnote-ref" id="fnref108"><sup>108</sup></a> A 2008 study concluded that, based on US data from the period 2000&lt;U+2013&gt;2002, adolescent-onset (defined here as ages 11&lt;U+2013&gt;17) usage of hallucinogenic drugs (including psilocybin) did not increase the risk of <a href="substance_dependence" title="wikilink">drug dependence</a> in adulthood; this was in contrast to adolescent usage of <a href="cannabis" class="uri" title="wikilink">cannabis</a>, <a href="cocaine" class="uri" title="wikilink">cocaine</a>, <a href="inhalant" title="wikilink">inhalants</a>, <a href="anxiolytic" class="uri" title="wikilink">anxiolytic</a> medicines, and <a href="stimulant" title="wikilink">stimulants</a>, all of which were associated with &quot;an excess risk of developing clinical features associated with drug dependence&quot;.<a href="#fn109" class="footnote-ref" id="fnref109"><sup>109</sup></a> Similarly, a 2010 Dutch study ranked the relative harm of psilocybin mushrooms compared to a selection of 19 <a href="recreational_drugs" title="wikilink">recreational drugs</a>, including alcohol, cannabis, cocaine, <a href="MDMA" title="wikilink">ecstasy</a>, <a href="heroin" class="uri" title="wikilink">heroin</a>, and <a href="tobacco" class="uri" title="wikilink">tobacco</a>. Magic mushrooms were ranked as the illicit drug with the lowest harm,<a href="#fn110" class="footnote-ref" id="fnref110"><sup>110</sup></a> corroborating conclusions reached earlier by expert groups in the United Kingdom.<a href="#fn111" class="footnote-ref" id="fnref111"><sup>111</sup></a><a href="#fn112" class="footnote-ref" id="fnref112"><sup>112</sup></a> Although no studies have linked psilocybin with <a href="birth_defects" title="wikilink">birth defects</a>,<a href="#fn113" class="footnote-ref" id="fnref113"><sup>113</sup></a> it is recommended that pregnant women avoid its usage.<a href="#fn114" class="footnote-ref" id="fnref114"><sup>114</sup></a></p>
<h2 id="physiology">Physiology</h2>
<p>Although psilocybin may be prepared synthetically, outside of the research setting, it is not typically used in this form. The psilocybin present in certain species of mushrooms can be ingested in several ways: by consuming fresh or dried fruit bodies, by preparing a <a href="herbal_tea" title="wikilink">tea</a>, or by combining with other foods to mask the bitter taste.<a href="#fn115" class="footnote-ref" id="fnref115"><sup>115</sup></a> Less frequently, mushroom extracts are injected <a href="intravenous" title="wikilink">intravenously</a>.<a href="#fn116" class="footnote-ref" id="fnref116"><sup>116</sup></a> The effects of the drug begin 10&lt;U+2013&gt;40 minutes after ingestion, and last 2&lt;U+2013&gt;6 hours depending on dose, species, and individual metabolism.<a href="#fn117" class="footnote-ref" id="fnref117"><sup>117</sup></a> The <a href="biological_half_life" title="wikilink">half life</a> of psilocybin is 163&lt;U+00B1&gt;64 minutes when taken orally, or 74.1&lt;U+00B1&gt;19.6 minutes when injected intravenously.<a href="#fn118" class="footnote-ref" id="fnref118"><sup>118</sup></a> A dosage of 4&lt;U+2013&gt;10 mg, corresponding roughly to 50&lt;U+2013&gt;300 <a href="microgram" title="wikilink">micrograms</a> per kilogram (&lt;U+00B5&gt;g/kg) of body weight, is required to induce psychedelic effects. A typical recreational dosage is 10&lt;U+2013&gt;50 mg psilocybin, which is roughly equivalent to 10&lt;U+2013&gt;50 grams of fresh mushrooms, or 1&lt;U+2013&gt;5 grams of dried mushrooms.<a href="#fn119" class="footnote-ref" id="fnref119"><sup>119</sup></a> However, a small number of people are unusually sensitive to psilocybin, such that a normally threshold-level dose of about 2 mg can result in effects usually associated with medium or high doses. Conversely, there are some who require relatively high doses to experience noticeable effects. Individual brain chemistry and metabolism play a large role in determining a person's response to psilocybin.<a href="#fn120" class="footnote-ref" id="fnref120"><sup>120</sup></a> <img src="Psilocybin_metabolism.svg" title="fig:Psilocybin is converted in the liver to the pharmacologically active psilocin, which is then either glucuronated to be excreted in the urine, or further converted to various psilocin metabolites." alt="Psilocybin is converted in the liver to the pharmacologically active psilocin, which is then either glucuronated to be excreted in the urine, or further converted to various psilocin metabolites." width="800" /> Psilocybin is metabolized mostly in the <a href="liver" class="uri" title="wikilink">liver</a>. As it becomes converted to psilocin, it undergoes a <a href="first-pass_effect" title="wikilink">first-pass effect</a>, whereby its concentration is greatly reduced before it reaches the <a href="systemic_circulation" title="wikilink">systemic circulation</a>. Psilocin is broken down by the enzyme <a href="monoamine_oxidase" title="wikilink">monoamine oxidase</a> to produce several <a href="metabolite" title="wikilink">metabolites</a> that can circulate in the blood plasma, including 4-hydroxyindole-3-acetaldehyde, 4-hydroxytryptophol, and 4-hydroxyindole-3-acetic acid.<a href="#fn121" class="footnote-ref" id="fnref121"><sup>121</sup></a> Some psilocin is not broken down by enzymes, and instead forms a <a href="glucuronide" class="uri" title="wikilink">glucuronide</a>; this is a biochemical mechanism animals use to eliminate toxic substances by linking them with <a href="glucuronic_acid" title="wikilink">glucuronic acid</a>, which can then be excreted in the urine.<a href="#fn122" class="footnote-ref" id="fnref122"><sup>122</sup></a><a href="#fn123" class="footnote-ref" id="fnref123"><sup>123</sup></a> Psilocin is glucuronated by the <a href="glucuronosyltransferase" class="uri" title="wikilink">glucuronosyltransferase</a> enzymes <a href="UGT1A9" class="uri" title="wikilink">UGT1A9</a> in the liver, and by <a href="UGT1A10" class="uri" title="wikilink">UGT1A10</a> in the small intestine.<a href="#fn124" class="footnote-ref" id="fnref124"><sup>124</sup></a> Based on <a href="animal_model" title="wikilink">studies using animals</a>, about 50% of ingested psilocybin is absorbed through the stomach and intestine. Within 24 hours, about 65% of the absorbed psilocybin is <a href="excretion" title="wikilink">excreted</a> into the urine, and a further 15&lt;U+2013&gt;20% is excreted in the <a href="bile" class="uri" title="wikilink">bile</a> and feces. Although most of the remaining drug is eliminated in this way within 8 hours, it is still detectable in the urine after 7 days.<a href="#fn125" class="footnote-ref" id="fnref125"><sup>125</sup></a> Clinical studies show that psilocin concentrations in the plasma of adults average about 8 &lt;U+00B5&gt;g/liter within 2 hours after ingestion of a single 15 mg oral psilocybin dose;<a href="#fn126" class="footnote-ref" id="fnref126"><sup>126</sup></a> psychological effects occur with a blood plasma concentration of 4&lt;U+2013&gt;6 &lt;U+00B5&gt;g/liter.<a href="#fn127" class="footnote-ref" id="fnref127"><sup>127</sup></a> Psilocybin is about 100 times less potent than LSD on a weight per weight basis, and the physiological effects last about half as long.<a href="#fn128" class="footnote-ref" id="fnref128"><sup>128</sup></a></p>
<p><a href="Drug_tolerance" title="wikilink">Tolerance</a> to psilocybin builds and dissipates quickly; ingesting psilocybin more than about once a week can lead to diminished effects. Tolerance dissipates after a few days, so doses can be spaced several days apart to avoid the effect.<a href="#fn129" class="footnote-ref" id="fnref129"><sup>129</sup></a> A <a href="cross-tolerance" class="uri" title="wikilink">cross-tolerance</a> can develop between psilocybin and the pharmacologically similar LSD,<a href="#fn130" class="footnote-ref" id="fnref130"><sup>130</sup></a> and between psilocybin and <a href="phenylethylamine" title="wikilink">phenylethylamines</a> such as <a href="mescaline" class="uri" title="wikilink">mescaline</a> and <a href="2,5-dimethoxy-4-methylamphetamine" class="uri" title="wikilink">2,5-dimethoxy-4-methylamphetamine</a>.<a href="#fn131" class="footnote-ref" id="fnref131"><sup>131</sup></a> <a href="Monoamine_oxidase_inhibitor" title="wikilink">Monoamine oxidase inhibitors</a> (MAOI) have been known to prolong and enhance the effects of psilocybin.<a href="#fn132" class="footnote-ref" id="fnref132"><sup>132</sup></a> Alcohol consumption may enhance the effects of psilocybin, because <a href="acetaldehyde" class="uri" title="wikilink">acetaldehyde</a>, one of the primary breakdown metabolites of consumed alcohol, reacts with <a href="biogenic_amines" title="wikilink">biogenic amines</a> present in the body to produce MAOIs related to <a href="tetrahydroisoquinoline" class="uri" title="wikilink">tetrahydroisoquinoline</a> and <a href="beta-carboline" title="wikilink">&lt;U+03B2&gt;-carboline</a>. Tobacco smokers can also experience more powerful effects with psilocybin,<a href="#fn133" class="footnote-ref" id="fnref133"><sup>133</sup></a> because tobacco smoke exposure decreases levels of MAO in the brain and peripheral organs.<a href="#fn134" class="footnote-ref" id="fnref134"><sup>134</sup></a></p>
<h2 id="effects">Effects</h2>
<p><img src="Timothy-Leary-Los-Angeles-1989.jpg" title="fig:American psychologist and counterculture figure Timothy Leary conducted early experiments into the effects of psychedelic drugs, including psilocybin." alt="American psychologist and counterculture figure Timothy Leary conducted early experiments into the effects of psychedelic drugs, including psilocybin." /> The effects of psilocybin are highly variable and depend on the mindset and environment in which the user has the experience, factors commonly referred to as <a href="set_and_setting" title="wikilink">set and setting</a>. In the early 1960s, <a href="Timothy_Leary" title="wikilink">Timothy Leary</a> and colleagues at Harvard University investigated the role of set and setting on the effects of psilocybin. They administered the drug to 175 volunteers from various backgrounds in an environment intended to be similar to a comfortable living room. Ninety-eight of the subjects were given questionnaires to assess their experiences and the contribution of background and situational factors. Individuals who had experience with psilocybin prior to the study reported more pleasant experiences than those for whom the drug was novel. Group size, dosage, preparation, and expectancy were important determinants of the drug response. Those placed in groups of more than eight individuals generally felt that the groups were less supportive, and their experiences were less pleasant. Conversely, smaller groups (fewer than six individuals) were seen as more supportive. Participants also reported having more positive reactions to the drug in those groups. Leary and colleagues proposed that psilocybin heightens <a href="suggestibility" class="uri" title="wikilink">suggestibility</a>, making an individual more receptive to interpersonal interactions and environmental stimuli.<a href="#fn135" class="footnote-ref" id="fnref135"><sup>135</sup></a> These findings were affirmed in a later review by Jos ten Berge (1999), who concluded that dosage, set, and setting were fundamental factors in determining the outcome of experiments that tested the effects of psychedelic drugs on artists' creativity.<a href="#fn136" class="footnote-ref" id="fnref136"><sup>136</sup></a></p>
<p>After ingesting psilocybin, a wide range of subjective effects may be experienced: feelings of <a href="disorientation" class="uri" title="wikilink">disorientation</a>, <a href="lethargy" class="uri" title="wikilink">lethargy</a>, giddiness, <a href="euphoria" class="uri" title="wikilink">euphoria</a>, joy, and <a href="depression_(mood)" title="wikilink">depression</a>. About a third of users report feelings of <a href="anxiety" class="uri" title="wikilink">anxiety</a> or <a href="paranoia" class="uri" title="wikilink">paranoia</a>.<a href="#fn137" class="footnote-ref" id="fnref137"><sup>137</sup></a> Low doses of the drug can induce hallucinatory effects. <a href="Closed-eye_hallucination" title="wikilink">Closed-eye hallucinations</a> may occur, in which the affected individual sees multicolored geometric shapes and vivid imaginative sequences.<a href="#fn138" class="footnote-ref" id="fnref138"><sup>138</sup></a> Some individuals report experiencing <a href="synesthesia" class="uri" title="wikilink">synesthesia</a>, such as tactile sensations when viewing colors.<a href="#fn139" class="footnote-ref" id="fnref139"><sup>139</sup></a> At higher doses, psilocybin can lead to &quot;Intensification of <a href="affect_(psychology)" title="wikilink">affective</a> responses, enhanced ability for introspection, <a href="regression_(psychology)" title="wikilink">regression</a> to primitive and childlike thinking, and activation of vivid memory traces with pronounced emotional undertones&quot;.<a href="#fn140" class="footnote-ref" id="fnref140"><sup>140</sup></a> Open-eye visual hallucinations are common, and may be very detailed although rarely confused with reality.<a href="#fn141" class="footnote-ref" id="fnref141"><sup>141</sup></a></p>
<p>A 2011 <a href="prospective_cohort" title="wikilink">prospective study</a> by Roland R. Griffiths and colleagues suggests that a single high dosage of psilocybin can cause long-term changes in the <a href="Personality_psychology" title="wikilink">personality</a> of its users. About half of the study participants&lt;U+2014&gt;described as healthy, &quot;spiritually active&quot;, and many possessing <a href="Postgraduate_diploma" title="wikilink">postgraduate degrees</a>&lt;U+2014&gt;showed an increase in the personality dimension of <a href="openness" class="uri" title="wikilink">openness</a> (assessed using the <a href="Revised_NEO_Personality_Inventory" title="wikilink">Revised NEO Personality Inventory</a>), and this positive effect was apparent more than a year after the psilocybin session. According to the study authors, the finding is significant because &quot;no study has prospectively demonstrated personality change in healthy adults after an experimentally manipulated discrete event.&quot;<a href="#fn142" class="footnote-ref" id="fnref142"><sup>142</sup></a> Although other researchers have described instances of psychedelic drug usage leading to new psychological understandings and personal insights,<a href="#fn143" class="footnote-ref" id="fnref143"><sup>143</sup></a> it is not known whether these experimental results can be generalized to larger populations.<a href="#fn144" class="footnote-ref" id="fnref144"><sup>144</sup></a></p>
<h3 id="physical-effects">Physical effects</h3>
<p>The physical <a href="side_effect" title="wikilink">side effects</a> resulting from psilocybin usage are generally not considered significant.<a href="#fn145" class="footnote-ref" id="fnref145"><sup>145</sup></a> Common responses include: <a href="Midriasis" title="wikilink">pupil dilation</a> (93%); changes in <a href="heart_rate" title="wikilink">heart rate</a> (100%), including increases (56%), decreases (13%), and variable responses (31%); changes in <a href="blood_pressure" title="wikilink">blood pressure</a> (84%), including <a href="hypotension" class="uri" title="wikilink">hypotension</a> (34%), <a href="hypertension" class="uri" title="wikilink">hypertension</a> (28%), and general instability (22%); changes in <a href="stretch_reflex" title="wikilink">stretch reflex</a> (86%), including increases (80%) and decreases (6%); nausea (44%); <a href="tremor" class="uri" title="wikilink">tremor</a> (25%); and <a href="dysmetria" class="uri" title="wikilink">dysmetria</a> (16%) (inability to properly direct or limit motions).{{#tag:ref|Percentages are derived from a <a href="Blind_experiment#Double-blind_trials" title="wikilink">non-blind</a> clinical study of 30 individuals who were given a dosage of 8&lt;U+2013&gt;12 milligrams of psilocybin; from Passie (2002),<a href="#fn146" class="footnote-ref" id="fnref146"><sup>146</sup></a> citing Quentin (1960).<a href="#fn147" class="footnote-ref" id="fnref147"><sup>147</sup></a>|group=nb}} The temporary increases in blood pressure caused by the drug can be a <a href="risk_factor" title="wikilink">risk factor</a> for users with pre-existing hypertension.<a href="#fn148" class="footnote-ref" id="fnref148"><sup>148</sup></a> These qualitative somatic effects caused by psilocybin have been corroborated by several early clinical studies.<ref>See for example:</p>
<ul>
<li></li>
<li></li>
<li></li>
<li></li>
<li><p></ref> A 2005 magazine survey of <a href="nightclub" title="wikilink">club</a> goers in the UK found that nausea or vomiting was experienced by over a quarter of those who had used hallucinogenic mushrooms in the last year, although this effect is caused by the mushroom rather than psilocybin itself.<a href="#fn149" class="footnote-ref" id="fnref149"><sup>149</sup></a> In one study, administration of gradually-increasing dosages of psilocybin daily for 21 days had no measurable effect on <a href="electrolyte" class="uri" title="wikilink">electrolyte</a> levels, <a href="blood_sugar" title="wikilink">blood sugar</a> levels, or <a href="Liver_function_tests" title="wikilink">liver toxicity tests</a>.<a href="#fn150" class="footnote-ref" id="fnref150"><sup>150</sup></a></p></li>
</ul>
<h3 id="perceptual-distortions">Perceptual distortions</h3>
<p><img src="Prefrontal_cortex.png" title="fig:The ability of psilocybin to cause perceptual distortions is linked to its influence on the activity of the prefrontal cortex." alt="The ability of psilocybin to cause perceptual distortions is linked to its influence on the activity of the prefrontal cortex." /> Psilocybin is known to strongly influence the subjective experience of the <a href="time_perception" title="wikilink">passage of time</a>.<a href="#fn151" class="footnote-ref" id="fnref151"><sup>151</sup></a> Users often feel as if time is slowed down, resulting in the perception that &quot;minutes appear to be hours&quot; or &quot;time is standing still&quot;.<a href="#fn152" class="footnote-ref" id="fnref152"><sup>152</sup></a> Studies have demonstrated that psilocybin significantly impairs subjects&lt;U+2019&gt; ability to gauge time intervals longer than 2.5 seconds, impairs their ability to synchronize to inter-beat intervals longer than 2 seconds, and reduces their preferred <a href="tapping_rate" title="wikilink">tapping rate</a>.<a href="#fn153" class="footnote-ref" id="fnref153"><sup>153</sup></a><a href="#fn154" class="footnote-ref" id="fnref154"><sup>154</sup></a> These results are consistent with the drug's role in affecting <a href="prefrontal_cortex" title="wikilink">prefrontal cortex</a> activity,<a href="#fn155" class="footnote-ref" id="fnref155"><sup>155</sup></a> and the role that the prefrontal cortex is known to play in time perception.<a href="#fn156" class="footnote-ref" id="fnref156"><sup>156</sup></a> However, the <a href="neurochemical" class="uri" title="wikilink">neurochemical</a> basis of psilocybin's effects on the perception of time are not known with certainty.<a href="#fn157" class="footnote-ref" id="fnref157"><sup>157</sup></a></p>
<p>Users having a pleasant experience can feel an ecstatic sense of connection to others, nature, and the universe; other perceptions and emotions are also often intensified. Users having an unpleasant experience (a &quot;<a href="bad_trip" title="wikilink">bad trip</a>&quot;) describe a reaction accompanied by fear, other unpleasant feelings, and occasionally by dangerous behavior. In general, the phrase &quot;bad trip&quot; is used to describe a reaction that is characterized primarily by fear or other unpleasant emotions, not just transitory experience of such feelings. A variety of factors may contribute to a psilocybin user experiencing a bad trip, including &quot;tripping&quot; during an emotional or physical low or in a non-supportive environment (see: <em><a href="set_and_setting" title="wikilink">set and setting</a></em>). Ingesting psilocybin in combination with other drugs, including alcohol, can also increase the likelihood of a bad trip.<a href="#fn158" class="footnote-ref" id="fnref158"><sup>158</sup></a><a href="#fn159" class="footnote-ref" id="fnref159"><sup>159</sup></a> Other than the duration of the experience, the effects of psilocybin are similar to comparable dosages of LSD or mescaline. In the <em>Psychedelics Encyclopedia</em>, author <a href="Peter_Stafford" title="wikilink">Peter Stafford</a> noted &quot;The psilocybin experience seems to be warmer, not as forceful and less isolating. It tends to build connections between people, who are generally much more in communication than when they use LSD.&quot;<a href="#fn160" class="footnote-ref" id="fnref160"><sup>160</sup></a></p>
<h3 id="possible-adverse-psychiatric-effects">Possible adverse psychiatric effects</h3>
<p>Panic reactions can occur after consumption of psilocybin-containing mushrooms, especially if the ingestion is accidental or otherwise unexpected. Reactions characterized by violence, aggression, homicidal and suicidal attempts,<a href="#fn161" class="footnote-ref" id="fnref161"><sup>161</sup></a> prolonged schizophrenia-like <a href="psychosis" class="uri" title="wikilink">psychosis</a>,<a href="#fn162" class="footnote-ref" id="fnref162"><sup>162</sup></a><a href="#fn163" class="footnote-ref" id="fnref163"><sup>163</sup></a> and <a href="convulsion" title="wikilink">convulsions</a><a href="#fn164" class="footnote-ref" id="fnref164"><sup>164</sup></a> have been reported in the literature. A 2005 survey conducted in the United Kingdom found that almost a quarter of those who had used psilocybin mushrooms in the past year had experienced a <a href="panic_attack" title="wikilink">panic attack</a>.<a href="#fn165" class="footnote-ref" id="fnref165"><sup>165</sup></a> Other adverse effects less frequently reported include <a href="paranoia" class="uri" title="wikilink">paranoia</a>, <a href="confusion" class="uri" title="wikilink">confusion</a>, <a href="derealization" class="uri" title="wikilink">derealization</a>, disconnection from reality, and <a href="mania" class="uri" title="wikilink">mania</a>.<a href="#fn166" class="footnote-ref" id="fnref166"><sup>166</sup></a> Psilocybin usage can temporarily induce a state of <a href="depersonalization_disorder" title="wikilink">depersonalization disorder</a>.<a href="#fn167" class="footnote-ref" id="fnref167"><sup>167</sup></a> Usage by those with <a href="schizophrenia" class="uri" title="wikilink">schizophrenia</a> can induce acute psychotic states requiring hospitalization.<a href="#fn168" class="footnote-ref" id="fnref168"><sup>168</sup></a></p>
<p>The similarity of psilocybin-induced symptoms to those of schizophrenia has made the drug a useful research tool in behavioral and <a href="neuroimaging" class="uri" title="wikilink">neuroimaging</a> studies of this psychotic disorder.<a href="#fn169" class="footnote-ref" id="fnref169"><sup>169</sup></a><a href="#fn170" class="footnote-ref" id="fnref170"><sup>170</sup></a><a href="#fn171" class="footnote-ref" id="fnref171"><sup>171</sup></a> In both cases, psychotic symptoms are thought to arise from a &quot;deficient gating of sensory and cognitive information&quot; in the brain that ultimately lead to &quot;cognitive fragmentation and psychosis&quot;.<a href="#fn172" class="footnote-ref" id="fnref172"><sup>172</sup></a> <a href="Flashback_(psychology)" title="wikilink">Flashbacks</a> (spontaneous recurrences of a previous psilocybin experience) can occur long after having used psilocybin mushrooms. <a href="Hallucinogen_persisting_perception_disorder" title="wikilink">Hallucinogen persisting perception disorder</a> (HPPD) is characterized by a continual presence of visual disturbances similar to those generated by psychedelic substances. Neither flashbacks nor HPPD are commonly associated with psilocybin usage,<a href="#fn173" class="footnote-ref" id="fnref173"><sup>173</sup></a> and correlations between HPPD and psychedelics are further obscured by <a href="polydrug_use" title="wikilink">polydrug use</a> and other variables.<a href="#fn174" class="footnote-ref" id="fnref174"><sup>174</sup></a></p>
<h2 id="mystical-experiences">Mystical experiences</h2>
<p>Psilocybin mushrooms have been and continue to be used in indigenous New World cultures in religious, <a href="divination" title="wikilink">divinatory</a>, or <a href="spirituality" title="wikilink">spiritual</a> contexts. Reflecting the meaning of the word <em>entheogen</em> (&quot;the god within&quot;), the mushrooms are revered as powerful spiritual <a href="sacrament" title="wikilink">sacraments</a> that provide access to sacred worlds. Typically used in small group community settings, they enhance <a href="group_cohesiveness" title="wikilink">group cohesion</a> and reaffirm <a href="traditional_values" title="wikilink">traditional values</a>.<a href="#fn175" class="footnote-ref" id="fnref175"><sup>175</sup></a> American philosopher <a href="Terence_McKenna" title="wikilink">Terence McKenna</a> documented the worldwide practices of psilocybin mushroom usage as part of a cultural <a href="ethos" class="uri" title="wikilink">ethos</a> relating to the Earth and mysteries of nature, and suggested that mushrooms enhanced <a href="self-awareness" class="uri" title="wikilink">self-awareness</a> and a sense of contact with a &quot;Transcendent Other&quot;&lt;U+2014&gt;reflecting a deeper and awareness of our connectedness with nature.<a href="#fn176" class="footnote-ref" id="fnref176"><sup>176</sup></a></p>
<p>Psychedelic drugs can induce states of <a href="consciousness" class="uri" title="wikilink">consciousness</a> that have lasting personal meaning and spiritual significance in individuals who are religious or spiritually inclined; these states are called <a href="mystical_experience" title="wikilink">mystical experiences</a>. Some scholars have proposed that many of the qualities of a drug-induced mystical experience are indistinguishable from mystical experiences achieved through <a href="Religious_experience#Causes_of_religious_experiences" title="wikilink">non-drug techniques</a>, such as <a href="meditation" class="uri" title="wikilink">meditation</a> or <a href="holotropic_breathwork" title="wikilink">holotropic breathwork</a>.<a href="#fn177" class="footnote-ref" id="fnref177"><sup>177</sup></a><a href="#fn178" class="footnote-ref" id="fnref178"><sup>178</sup></a> In the 1960s, <a href="Walter_Pahnke" title="wikilink">Walter Pahnke</a> and colleagues systematically evaluated mystical experiences (which they called &quot;mystical consciousness&quot;) by categorizing their common features. These categories, according to Pahnke, &quot;describe the core of a universal psychological experience, free from culturally determined philosophical or theological interpretations&quot;, and allow researchers to assess mystical experiences on a qualitative, numerical scale.<a href="#fn179" class="footnote-ref" id="fnref179"><sup>179</sup></a></p>
<p>In the 1962 <a href="Marsh_Chapel_Experiment" title="wikilink">Marsh Chapel Experiment</a>, which was run by Pahnke at the <a href="Harvard_Divinity_School" title="wikilink">Harvard Divinity School</a> under the supervision of Timothy Leary,<a href="#fn180" class="footnote-ref" id="fnref180"><sup>180</sup></a> almost all of the graduate degree <a href="seminary" title="wikilink">divinity</a> student volunteers who received psilocybin reported profound religious experiences.<a href="#fn181" class="footnote-ref" id="fnref181"><sup>181</sup></a> One of the participants was religious scholar <a href="Huston_Smith" title="wikilink">Huston Smith</a>, author of several textbooks on <a href="comparative_religion" title="wikilink">comparative religion</a>; he later described his experience as &quot;the most powerful cosmic homecoming I have ever experienced.&quot;<a href="#fn182" class="footnote-ref" id="fnref182"><sup>182</sup></a> In a 25-year followup to the experiment, all of the subjects given psilocybin described their experience as having elements of &quot;a genuine mystical nature and characterized it as one of the high points of their spiritual life&quot;.<a href="#fn183" class="footnote-ref" id="fnref183"><sup>183</sup></a> Psychedelic researcher <a href="Rick_Doblin" title="wikilink">Rick Doblin</a> considered the study partially flawed due to incorrect implementation of the <a href="double-blind" class="uri" title="wikilink">double-blind</a> procedure, and several imprecise questions in the mystical experience questionnaire. Nevertheless, he said that the study cast &quot;a considerable doubt on the assertion that mystical experiences catalyzed by drugs are in any way inferior to non-drug mystical experiences in both their immediate content and long-term effects&quot;.<a href="#fn184" class="footnote-ref" id="fnref184"><sup>184</sup></a> This sentiment was echoed by psychiatrist William A. Richards, who in a 2007 review stated &quot;[psychedelic] mushroom use may constitute one technology for evoking revelatory experiences that are similar, if not identical, to those that occur through so-called spontaneous alterations of brain chemistry.&quot;<a href="#fn185" class="footnote-ref" id="fnref185"><sup>185</sup></a> <img src="Johns_Hopkins_psilocybin_session_room-SessionRm_2176x.jpg" title="fig:In their studies on the psilocybin experience, Johns Hopkins researchers use peaceful music and a comfortable room to help ensure a comfortable setting, and experienced guides to monitor and reassure the volunteers." alt="In their studies on the psilocybin experience, Johns Hopkins researchers use peaceful music and a comfortable room to help ensure a comfortable setting, and experienced guides to monitor and reassure the volunteers." /> A group of researchers from <a href="Johns_Hopkins_School_of_Medicine" title="wikilink">Johns Hopkins School of Medicine</a> led by Griffiths conducted a study to assess the immediate and long-term psychological effects of the psilocybin experience, using a modified version of the mystical experience questionnaire and a rigorous double-blind procedure.<a href="#fn186" class="footnote-ref" id="fnref186"><sup>186</sup></a> When asked in an interview about the similarity of his work with Leary's, Griffiths explained the difference: &quot;We are conducting rigorous, systematic research with psilocybin under carefully monitored conditions, a route which Dr. Leary abandoned in the early 1960s.&quot;<a href="#fn187" class="footnote-ref" id="fnref187"><sup>187</sup></a> The <a href="National_Institute_of_Drug_Abuse" title="wikilink">National Institute of Drug Abuse</a>-funded study, published in 2006, has been praised by experts for the soundness of its experimental design.{{#tag:ref|The academic communities' approval for the methodology employed is exemplified by the quartet of commentaries published in the journal <em><a href="Psychopharmacology_(journal)" title="wikilink">Psychopharmacology</a></em> titled &quot;<a href="http://www.hopkinsmedicine.org/Press_releases/2006/GriffithsCommentaries.pdf">Commentary on: Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual experience by Griffiths <em>et al</em>.</a>&quot;, by HD Kleber (pp. 291&lt;U+2013&gt;2), DE Nichols (pp. 284&lt;U+2013&gt;6), CR Schuster (pp. 289&lt;U+2013&gt;90), and SH Snyder (pp. 287&lt;U+2013&gt;8).|group=nb}} In the experiment, 36 volunteers without prior experience with hallucinogens were given psilocybin and <a href="methylphenidate" class="uri" title="wikilink">methylphenidate</a> (Ritalin) in separate sessions; the methylphenidate sessions served as a <a href="Scientific_control" title="wikilink">control</a> and <a href="psychoactive_placebo" title="wikilink">psychoactive placebo</a>. The degree of mystical experience was measured using a questionnaire developed by Ralph W. Hood;<a href="#fn188" class="footnote-ref" id="fnref188"><sup>188</sup></a> 61% of subjects reported a &quot;complete mystical experience&quot; after their psilocybin session, while only 13% reported such an outcome after their experience with methylphenidate. Two months after taking psilocybin, 79% of the participants reported moderately to greatly increased life satisfaction and sense of well-being. About 36% of participants also had a strong to extreme &lt;U+201C&gt;experience of fear&lt;U+201D&gt; or <a href="dysphoria" class="uri" title="wikilink">dysphoria</a> (i.e., a &lt;U+201C&gt;bad trip&lt;U+201D&gt;) at some point during the psilocybin session (which was not reported by any subject during the methylphenidate session), with about one-third of these (13% of the total) reporting that this dysphoria dominated the entire session. These negative effects were reported to be easily managed by the researchers and did not have a lasting negative effect on the subject&lt;U+2019&gt;s sense of well-being.<a href="#fn189" class="footnote-ref" id="fnref189"><sup>189</sup></a></p>
<p>A followup study conducted 14 months after the original psilocybin session confirmed that participants continued to attribute deep personal meaning to the experience. Almost one-third of the subjects reported that the experience was the single most meaningful or spiritually significant event of their lives, and over two-thirds reported it among their five most spiritually significant events. About two-thirds indicated that the experience increased their sense of well-being or life satisfaction.<a href="#fn190" class="footnote-ref" id="fnref190"><sup>190</sup></a> Similarly, in a recent (2010) web-based questionnaire study designed to investigate user perceptions of the benefits and harms of hallucinogenic drug use, 60% of the 503 psilocybin users reported that their use of psilocybin had a long-term positive impact on their sense of well-being.<a href="#fn191" class="footnote-ref" id="fnref191"><sup>191</sup></a><a href="#fn192" class="footnote-ref" id="fnref192"><sup>192</sup></a></p>
<p>In 2011, Griffiths and colleagues published the results of further studies designed to learn more about the optimum psilocybin doses needed for positive life-changing experiences, while minimizing the chance of negative reactions. In a 14-month followup, the researchers found that 94% of the volunteers rated their experiences with the drug as one of the top five most spiritually significant of their lives (44% said it was the single most significant). None of the 90 sessions that took place throughout the study were rated as decreasing well-being or life satisfaction. Moreover, 89% reported positive changes in their behaviors as a result of the experiences. The conditions of the experimental design included a single drug experience a month, on a couch, in a living-room-like setting, with eye shades and carefully chosen music (classical and world music). As an additional precaution to guide the experience, the 2011 study included a &quot;monitor&quot; whom the volunteers supposedly trusted. The monitors provided gentle reassurance when the volunteers experienced anxiety. The volunteers, monitors, and observers all remained <a href="blind_experiment" title="wikilink">blind</a> to the exact dosages for the sake of the experiment.<a href="#fn193" class="footnote-ref" id="fnref193"><sup>193</sup></a></p>
<h2 id="medical-research">Medical research</h2>
<p>Psilocybin has been a subject of <a href="medical_research" title="wikilink">medical research</a> since the 1960s, when Leary and Alpert ran the <a href="Harvard_Psilocybin_Project" title="wikilink">Harvard Psilocybin Project</a>, in which they carried out a number of experiments to evaluate the therapeutic value of psilocybin in the treatment of personality disorders, or to augment <a href="psychological_counseling" title="wikilink">psychological counseling</a>.<a href="#fn194" class="footnote-ref" id="fnref194"><sup>194</sup></a> In the 2000s (decade), there has been a renewal of research concerning the use of psychedelic drugs for potential clinical applications, such as to address <a href="anxiety_disorder" title="wikilink">anxiety disorders</a>, <a href="major_depression" title="wikilink">major depression</a>, and various <a href="addiction" title="wikilink">addictions</a>.<a href="#fn195" class="footnote-ref" id="fnref195"><sup>195</sup></a><a href="#fn196" class="footnote-ref" id="fnref196"><sup>196</sup></a> In 2008, the Johns Hopkins research team published guidelines for responsibly conducting medical research <a href="clinical_trial" title="wikilink">trials</a> with psilocybin and other hallucinogens in humans. These included recommendations on how to screen potential study volunteers to exclude those with personal or family <a href="psychiatric_history" title="wikilink">psychiatric histories</a> that suggest a risk of averse reactions to hallucinogens.<a href="#fn197" class="footnote-ref" id="fnref197"><sup>197</sup></a> A 2010 study on the short- and long-term subjective effects of psilocybin administration in clinical settings concluded that despite a small risk of <a href="acute_(medicine)" title="wikilink">acute</a> reactions such as dysphoria, anxiety, or panic, &quot;the administration of moderate doses of psilocybin to healthy, high-functioning and well-prepared subjects in the context of a carefully monitored research environment is associated with an acceptable level of risk&quot;; the authors note, however, that the safety of the drug &quot;cannot be generalized to situations in which psilocybin is used recreationally or administered under less controlled conditions.&quot;<a href="#fn198" class="footnote-ref" id="fnref198"><sup>198</sup></a></p>
<p>The first <a href="FDA_approval#Regulatory_programs" title="wikilink">FDA-approved</a> clinical study of psilocybin since 1970<a href="#fn199" class="footnote-ref" id="fnref199"><sup>199</sup></a>&lt;U+2014&gt;led by Francisco Moreno at the <a href="University_of_Arizona" title="wikilink">University of Arizona</a> and supported by the <a href="Multidisciplinary_Association_for_Psychedelic_Studies" title="wikilink">Multidisciplinary Association for Psychedelic Studies</a>&lt;U+2014&gt;studied the effects of psilocybin on nine patients with <a href="obsessive-compulsive_disorder" title="wikilink">obsessive-compulsive disorder</a> (OCD).<a href="#fn200" class="footnote-ref" id="fnref200"><sup>200</sup></a><a href="#fn201" class="footnote-ref" id="fnref201"><sup>201</sup></a> The <a href="pilot_study" title="wikilink">pilot study</a> found that, when administered by trained professionals in a medical setting, the use of psilocybin was associated with substantial reductions in OCD symptoms in several of the patients.<a href="#fn202" class="footnote-ref" id="fnref202"><sup>202</sup></a> This effect may be caused by psilocybin's ability to <a href="Downregulation_and_upregulation" title="wikilink">reduce the levels</a> of the serotonin-2A receptor, resulting in decreased responsiveness to serotonin.<a href="#fn203" class="footnote-ref" id="fnref203"><sup>203</sup></a> Psilocybin has additionally shown promise to ease the pain caused by <a href="cluster_headache" title="wikilink">cluster headaches</a>, often considered not only the most painful of all types of headaches<a href="#fn204" class="footnote-ref" id="fnref204"><sup>204</sup></a> but &quot;one of the worst pain syndromes known to mankind.&quot;<a href="#fn205" class="footnote-ref" id="fnref205"><sup>205</sup></a> In a 2006 study,<a href="#fn206" class="footnote-ref" id="fnref206"><sup>206</sup></a> half of cluster headache patients reported that psilocybin aborted the attacks, and most reported extended <a href="Remission_(medicine)#Remission" title="wikilink">remission periods</a>; similar results were reported for LSD.<a href="#fn207" class="footnote-ref" id="fnref207"><sup>207</sup></a> A 2011 review of <a href="Alternative_medicine" title="wikilink">alternative</a> headache treatments concluded that, despite flaws in the study design, these results suggest that LSD and psilocybin may warrant further study for use in the prevention of cluster headaches&lt;U+2014&gt;only subhallucinogenic doses of the drugs are required for effective treatment, and no other medications have been reported to stop a cluster headache cycle.<a href="#fn208" class="footnote-ref" id="fnref208"><sup>208</sup></a></p>
<p>Several modern studies have investigated the possibility that psilocybin can ease the psychological suffering associated with <a href="Terminal_illness" title="wikilink">end-stage</a> cancer. Preliminary results indicate that low doses of psilocybin can improve the mood and reduce the anxiety of patients with advanced cancer, and that the effects last from two weeks to six months.<a href="#fn209" class="footnote-ref" id="fnref209"><sup>209</sup></a> These results are comparable to those obtained from early studies that explored the use of LSD to improve the psychological well-being of terminally ill patients, but without the experimental rigor employed in modern clinical <a href="psychopharmacology" class="uri" title="wikilink">psychopharmacology</a> research.<a href="#fn210" class="footnote-ref" id="fnref210"><sup>210</sup></a><a href="#fn211" class="footnote-ref" id="fnref211"><sup>211</sup></a></p>
<h2 id="social-and-legal-aspects">Social and legal aspects</h2>

<p>A 2009 national survey of drug use by the <a href="US_Department_of_Health_and_Human_Services" title="wikilink">US Department of Health and Human Services</a> concluded that the number of first-time psilocybin mushroom users in the United States was roughly equivalent to the number of first-time users of <a href="marijuana" class="uri" title="wikilink">marijuana</a>.<a href="#fn212" class="footnote-ref" id="fnref212"><sup>212</sup></a> In European countries, the lifetime prevalence estimates of psychedelic mushroom usage among young adults (15&lt;U+2013&gt;34 years) range from 0.3% to 14.1%.<a href="#fn213" class="footnote-ref" id="fnref213"><sup>213</sup></a> In modern Mexico, traditional ceremonial use survives among several indigenous groups, including the <a href="Nahuatl" title="wikilink">Nahuatls</a>, the <a href="Matlazinca" class="uri" title="wikilink">Matlazinca</a>, the <a href="Totonacs" class="uri" title="wikilink">Totonacs</a>, the <a href="Mazatecs" class="uri" title="wikilink">Mazatecs</a>, <a href="Mixe_people" title="wikilink">Mixes</a>, <a href="Zapotec_peoples" title="wikilink">Zapotecs</a>, and the <a href="Chatino" class="uri" title="wikilink">Chatino</a>. Although hallucinogenic <em>Psilocybe</em> species are abundant in low-lying areas of Mexico, most ceremonial use takes places in mountainous areas of elevations greater than . Guzm&lt;U+00E1&gt;n suggests this is a vestige of Spanish colonial influence from several hundred years earlier, when mushroom use was persecuted by the <a href="Catholic_Church" title="wikilink">Catholic Church</a>.<a href="#fn214" class="footnote-ref" id="fnref214"><sup>214</sup></a></p>
<p>In the United States, psilocybin (and psilocin) were first subjected to federal regulation by the Drug Abuse Control Amendments of 1965, a product of a <a href="Bill_(proposed_law)" title="wikilink">bill</a> sponsored by Senator <a href="Thomas_J._Dodd" title="wikilink">Thomas J. Dodd</a>. The law&lt;U+2014&gt;passed in July 1965 and effected on February 1, 1966&lt;U+2014&gt;was an amendment to the federal <a href="Food,_Drug_and_Cosmetic_Act" title="wikilink">Food, Drug and Cosmetic Act</a> and was intended to regulate the unlicensed &quot;possession, manufacture, or sale of depressant, stimulant and hallucinogenic drugs&quot;.<a href="#fn215" class="footnote-ref" id="fnref215"><sup>215</sup></a> The <a href="statute" title="wikilink">statutes</a> themselves, however, did not list the &quot;hallucinogenic drugs&quot; that were being regulated.<a href="#fn216" class="footnote-ref" id="fnref216"><sup>216</sup></a> Instead, the term &quot;hallucinogenic drugs&quot; was meant to refer to those substances believed to have a &quot;hallucinogenic effect on the central nervous system&quot;.<a href="#fn217" class="footnote-ref" id="fnref217"><sup>217</sup></a> <img src="Dried_Cubensis.jpg" title="fig:Dried Psilocybe mushrooms showing the characteristic blue bruising on the stems" alt="Dried Psilocybe mushrooms showing the characteristic blue bruising on the stems" /> Despite the seemingly strict provisions of the law, many people were exempt from prosecution. The statutes &quot;permit[ted] &lt;U+2026&gt; people to possess such drugs so long as they were for the personal use of the possessor, [for] a member of his household, or for administration to an animal&quot;.<a href="#fn218" class="footnote-ref" id="fnref218"><sup>218</sup></a> The federal law that specifically banned psilocybin and psilocin was enacted on October 24, 1968. The substances were said to have &quot;a high potential for abuse&quot;, &quot;no currently accepted medical use,&quot; and &quot;a lack of accepted safety&quot;.<a href="#fn219" class="footnote-ref" id="fnref219"><sup>219</sup></a> On October 27, 1970, both psilocybin and psilocin became classified as <a href="Controlled_Substances_Act#Schedule_I_controlled_substances" title="wikilink">Schedule I</a> drugs and were simultaneously labeled &quot;hallucinogens&quot; under a section of the <a href="Comprehensive_Drug_Abuse_Prevention_and_Control_Act_of_1970" title="wikilink">Comprehensive Drug Abuse Prevention and Control Act</a> known as the <a href="Controlled_Substances_Act" title="wikilink">Controlled Substances Act</a>.<a href="#fn220" class="footnote-ref" id="fnref220"><sup>220</sup></a> Schedule I drugs are illicit drugs that are claimed to have no known therapeutic benefit. The <a href="United_Nations" title="wikilink">United Nations</a> <a href="Convention_on_Psychotropic_Substances" title="wikilink">Convention on Psychotropic Substances</a> (adopted in 1971) requires its members to prohibit psilocybin, and parties to the treaty are required to restrict use of the drug to medical and scientific research under strictly controlled conditions. However, the mushrooms containing the drug were not specifically included in the convention, due largely to pressure from the <a href="Mexican_government" title="wikilink">Mexican government</a>.<a href="#fn221" class="footnote-ref" id="fnref221"><sup>221</sup></a> Most national <a href="Prohibition_(drugs)" title="wikilink">drug laws</a> have been amended to reflect the terms of the convention; examples include the UK <a href="Misuse_of_Drugs_Act_1971" title="wikilink">Misuse of Drugs Act 1971</a>, the US <a href="Psychotropic_Substances_Act_(United_States)" title="wikilink">Psychotropic Substances Act</a> of 1978,<a href="#fn222" class="footnote-ref" id="fnref222"><sup>222</sup></a> the Canadian <a href="Controlled_Drugs_and_Substances_Act" title="wikilink">Controlled Drugs and Substances Act</a> of 1996,<a href="#fn223" class="footnote-ref" id="fnref223"><sup>223</sup></a> and the Japanese Narcotics and Psychotropics Control Law of 2002.<a href="#fn224" class="footnote-ref" id="fnref224"><sup>224</sup></a> The possession and use of psilocybin is prohibited under almost all circumstances, and often carries severe legal penalties.<a href="#fn225" class="footnote-ref" id="fnref225"><sup>225</sup></a></p>
<p>Possession and use of psilocybin mushrooms, including the bluing species of <em>Psilocybe</em>, is therefore prohibited by extension. However, in many national, state, and provincial drug laws, there has been a great deal of ambiguity about the legal status of psilocybin mushrooms, as well as a strong element of <a href="selective_enforcement" title="wikilink">selective enforcement</a> in some places.<a href="#fn226" class="footnote-ref" id="fnref226"><sup>226</sup></a><a href="#fn227" class="footnote-ref" id="fnref227"><sup>227</sup></a> Most US <a href="State_court_(United_States)" title="wikilink">state courts</a> have considered the mushroom a 'container' of the illicit drugs, and therefore illegal. A <a href="loophole" class="uri" title="wikilink">loophole</a> further complicates the legal situation&lt;U+2014&gt;the spores of psilocybin mushrooms do not contain the drugs, and are legal to possess in many areas. Jurisdictions that have specifically enacted or amended laws to criminalize the possession of psilocybin mushroom spores include Germany (since 1998),<a href="#fn228" class="footnote-ref" id="fnref228"><sup>228</sup></a> and <a href="California" class="uri" title="wikilink">California</a>, <a href="Georgia_(US_state)" title="wikilink">Georgia</a>, and <a href="Idaho" class="uri" title="wikilink">Idaho</a> in the United States. There is consequently an active <a href="underground_economy" title="wikilink">underground economy</a> involved in the sale of spores and cultivation materials, and an internet-based social network to support the illicit activity.<a href="#fn229" class="footnote-ref" id="fnref229"><sup>229</sup></a> After a long interruption in the use of these psilocybin in research, there has been a general shift in attitudes regarding research with hallucinogenic agents. Many countries are revising their positions and have started to approve studies to test the physiological and therapeutic effects of hallucinogens.<a href="#fn230" class="footnote-ref" id="fnref230"><sup>230</sup></a></p>
<h2 id="see-also">See also</h2>

<div style="column-count:2;-moz-column-count:2;-webkit-column-count:2">
<ul>
<li><a href="Psychedelic_experience" title="wikilink">Psychedelic experience</a></li>
<li><a href="List_of_entheogens" title="wikilink">List of entheogens</a></li>
<li><a href="O-Acetylpsilocin" title="wikilink"><em>O</em>-Acetylpsilocin</a></li>
<li><a href="Psychedelic_plants" title="wikilink">Psychedelic plants</a></li>
<li><a href="Psychoactive_drug" title="wikilink">Psychoactive drug</a></li>
<li><a href="Soma" class="uri" title="wikilink">Soma</a></li>
</ul>
</div>
<h2 id="notes">Notes</h2>
<references group="nb" />
<h2 id="references">References</h2>

<h3 id="cited-literature">Cited literature</h3>

<ul>
<li></li>
<li></li>
<li></li>
<li></li>
<li></li>
<li></li>
<li></li>
<li></li>
<li></li>
</ul>

<h2 id="external-links">External links</h2>
<ul>
<li><a href="http://www.csp.org/psilocybin">Hopkins/CSP research findings and media reports, 2006, 2008, 2011</a></li>
<li><a href="http://www.maps.org/research/index.html#PSILOCYBIN">MAPS</a> Psilocybin research</li>
</ul>




<p><a href="bg:&lt;U+041F&gt;&lt;U+0441&gt;&lt;U+0438&gt;&lt;U+043B&gt;&lt;U+043E&gt;&lt;U+0446&gt;&lt;U+0438&gt;&lt;U+0431&gt;&lt;U+0438&gt;&lt;U+043D&gt;" class="uri" title="wikilink">bg:&lt;U+041F&gt;&lt;U+0441&gt;&lt;U+0438&gt;&lt;U+043B&gt;&lt;U+043E&gt;&lt;U+0446&gt;&lt;U+0438&gt;&lt;U+0431&gt;&lt;U+0438&gt;&lt;U+043D&gt;</a> <a href="ca:Psilocibina" class="uri" title="wikilink">ca:Psilocibina</a> <a href="cs:Psilocybin" class="uri" title="wikilink">cs:Psilocybin</a> <a href="da:Psilocybin" class="uri" title="wikilink">da:Psilocybin</a> <a href="de:Psilocybin" class="uri" title="wikilink">de:Psilocybin</a> <a href="et:Psilots&lt;U+00FC&gt;biin" class="uri" title="wikilink">et:Psilots&lt;U+00FC&gt;biin</a> <a href="es:Psilocibina" class="uri" title="wikilink">es:Psilocibina</a> <a href="fa:&lt;U+0633&gt;&lt;U+06CC&gt;&lt;U+0644&gt;&lt;U+0648&gt;&lt;U+0633&gt;&lt;U+0627&gt;&lt;U+06CC&gt;&lt;U+0628&gt;&lt;U+06CC&gt;&lt;U+0646&gt;" class="uri" title="wikilink">fa:&lt;U+0633&gt;&lt;U+06CC&gt;&lt;U+0644&gt;&lt;U+0648&gt;&lt;U+0633&gt;&lt;U+0627&gt;&lt;U+06CC&gt;&lt;U+0628&gt;&lt;U+06CC&gt;&lt;U+0646&gt;</a> <a href="fr:Psilocybine" class="uri" title="wikilink">fr:Psilocybine</a> <a href="ko:&lt;U+C2E4&gt;&lt;U+B85C&gt;&lt;U+C2DC&gt;&lt;U+BE48&gt;" class="uri" title="wikilink">ko:&lt;U+C2E4&gt;&lt;U+B85C&gt;&lt;U+C2DC&gt;&lt;U+BE48&gt;</a> <a href="hr:Psilocibin" class="uri" title="wikilink">hr:Psilocibin</a> <a href="io:Psilocibino" class="uri" title="wikilink">io:Psilocibino</a> <a href="it:Psilocibina" class="uri" title="wikilink">it:Psilocibina</a> <a href="he:&lt;U+05E4&gt;&lt;U+05E1&gt;&lt;U+05D9&gt;&lt;U+05DC&gt;&lt;U+05D5&gt;&lt;U+05E6&gt;&lt;U+05D9&gt;&lt;U+05D1&gt;&lt;U+05D9&gt;&lt;U+05DF&gt;" class="uri" title="wikilink">he:&lt;U+05E4&gt;&lt;U+05E1&gt;&lt;U+05D9&gt;&lt;U+05DC&gt;&lt;U+05D5&gt;&lt;U+05E6&gt;&lt;U+05D9&gt;&lt;U+05D1&gt;&lt;U+05D9&gt;&lt;U+05DF&gt;</a> <a href="lv:Psilocib&lt;U+012B&gt;ns" class="uri" title="wikilink">lv:Psilocib&lt;U+012B&gt;ns</a> <a href="lt:Psilocibinas" class="uri" title="wikilink">lt:Psilocibinas</a> <a href="hu:Pszilocibin" class="uri" title="wikilink">hu:Pszilocibin</a> <a href="nl:Psilocybine" class="uri" title="wikilink">nl:Psilocybine</a> <a href="ja:&lt;U+30B7&gt;&lt;U+30ED&gt;&lt;U+30B7&gt;&lt;U+30D3&gt;&lt;U+30F3&gt;" class="uri" title="wikilink">ja:&lt;U+30B7&gt;&lt;U+30ED&gt;&lt;U+30B7&gt;&lt;U+30D3&gt;&lt;U+30F3&gt;</a> <a href="no:Psilocybin" class="uri" title="wikilink">no:Psilocybin</a> <a href="pl:Psylocybina" class="uri" title="wikilink">pl:Psylocybina</a> <a href="pt:Psilocibina" class="uri" title="wikilink">pt:Psilocibina</a> <a href="ru:&lt;U+041F&gt;&lt;U+0441&gt;&lt;U+0438&gt;&lt;U+043B&gt;&lt;U+043E&gt;&lt;U+0446&gt;&lt;U+0438&gt;&lt;U+0431&gt;&lt;U+0438&gt;&lt;U+043D&gt;" class="uri" title="wikilink">ru:&lt;U+041F&gt;&lt;U+0441&gt;&lt;U+0438&gt;&lt;U+043B&gt;&lt;U+043E&gt;&lt;U+0446&gt;&lt;U+0438&gt;&lt;U+0431&gt;&lt;U+0438&gt;&lt;U+043D&gt;</a> <a href="simple:Psilocybin" class="uri" title="wikilink">simple:Psilocybin</a> <a href="sk:Psilocyb&lt;U+00ED&gt;n" class="uri" title="wikilink">sk:Psilocyb&lt;U+00ED&gt;n</a> <a href="sr:Psilocibin" class="uri" title="wikilink">sr:Psilocibin</a> <a href="sh:Psilocibin" class="uri" title="wikilink">sh:Psilocibin</a> <a href="fi:Psilosybiini" class="uri" title="wikilink">fi:Psilosybiini</a> <a href="sv:Psilocybin" class="uri" title="wikilink">sv:Psilocybin</a> <a href="tr:Psilocybin" class="uri" title="wikilink">tr:Psilocybin</a> <a href="uk:&lt;U+041F&gt;&lt;U+0441&gt;&lt;U+0438&gt;&lt;U+043B&gt;&lt;U+043E&gt;&lt;U+0446&gt;&lt;U+0438&gt;&lt;U+0431&gt;&lt;U+0456&gt;&lt;U+043D&gt;" class="uri" title="wikilink">uk:&lt;U+041F&gt;&lt;U+0441&gt;&lt;U+0438&gt;&lt;U+043B&gt;&lt;U+043E&gt;&lt;U+0446&gt;&lt;U+0438&gt;&lt;U+0431&gt;&lt;U+0456&gt;&lt;U+043D&gt;</a> <a href="zh:&lt;U+88F8&gt;&lt;U+76D6&gt;&lt;U+83C7&gt;&lt;U+7D20&gt;" class="uri" title="wikilink">zh:&lt;U+88F8&gt;&lt;U+76D6&gt;&lt;U+83C7&gt;&lt;U+7D20&gt;</a></p>
<p><a href="Category:Entheogens" class="uri" title="wikilink">Category:Entheogens</a> <a href="Category:Light-sensitive_chemicals" title="wikilink">Category:Light-sensitive chemicals</a> <a href="Category:Mycotoxins" class="uri" title="wikilink">Category:Mycotoxins</a> <a href="Category:Natural_tryptamine_alkaloids" title="wikilink">Category:Natural tryptamine alkaloids</a> <a href="Category:Novartis" class="uri" title="wikilink">Category:Novartis</a> <a href="Category:Organophosphates" class="uri" title="wikilink">Category:Organophosphates</a> <a href="Category:Psychedelic_tryptamines" title="wikilink">Category:Psychedelic tryptamines</a> <a href="Category:Serotonin_receptor_agonists" title="wikilink">Category:Serotonin receptor agonists</a></p>
<section class="footnotes">
<hr />
<ol>
<li id="fn1"></li>
<li id="fn2"></li>
<li id="fn3"></li>
<li id="fn4">Stamets (1996), p. 11.<a href="#fnref4" class="footnote-back">↩</a></li>
<li id="fn5">Marley (2010), p. 164.<a href="#fnref5" class="footnote-back">↩</a></li>
<li id="fn6"></li>
<li id="fn7">Marley (2010), p. 165.<a href="#fnref7" class="footnote-back">↩</a></li>
<li id="fn8">Gartz (1997), pp. 10&lt;U+2013&gt;2.<a href="#fnref8" class="footnote-back">↩</a></li>
<li id="fn9">Gartz (1997), p. 16.<a href="#fnref9" class="footnote-back">↩</a></li>
<li id="fn10"></li>
<li id="fn11"></li>
<li id="fn12"></li>
<li id="fn13"></li>
<li id="fn14"></li>
<li id="fn15">Stafford (1992), <a href="http://books.google.com/books?id=o4_pLqCOyDsC&amp;pg=PA237">p. 237.</a><a href="#fnref15" class="footnote-back">↩</a></li>
<li id="fn16"></li>
<li id="fn17">Marley (2010), p. 166.<a href="#fnref17" class="footnote-back">↩</a></li>
<li id="fn18"></li>
<li id="fn19"></li>
<li id="fn20"></li>
<li id="fn21"></li>
<li id="fn22"></li>
<li id="fn23"></li>
<li id="fn24">Ott (1993), p. 276.<a href="#fnref24" class="footnote-back">↩</a></li>
<li id="fn25"></li>
<li id="fn26">Ott (1993), p. 290. San Antonio's technique describes a method to grow the common edible mushroom <em><a href="Agaricus_bisporus" title="wikilink">Agaricus bisporus</a></em>; see <a href="#fnref26" class="footnote-back">↩</a></li>
<li id="fn27"></li>
<li id="fn28"></li>
<li id="fn29"></li>
<li id="fn30"></li>
<li id="fn31"></li>
<li id="fn32"></li>
<li id="fn33">Wurst <em>et al</em>. (2002), p. 5.<a href="#fnref33" class="footnote-back">↩</a></li>
<li id="fn34"></li>
<li id="fn35"></li>
<li id="fn36"></li>
<li id="fn37"></li>
<li id="fn38">Stamets (1996), p. 39.<a href="#fnref38" class="footnote-back">↩</a></li>
<li id="fn39"></li>
<li id="fn40"></li>
<li id="fn41"></li>
<li id="fn42"></li>
<li id="fn43"></li>
<li id="fn44">Stafford (1992), <a href="http://books.google.com/books?id=o4_pLqCOyDsC&amp;pg=PA248">p. 248.</a><a href="#fnref44" class="footnote-back">↩</a></li>
<li id="fn45">Stamets (1996), pp. 36&lt;U+2013&gt;41, 52.<a href="#fnref45" class="footnote-back">↩</a></li>
<li id="fn46"></li>
<li id="fn47">Stamets (1996), pp. 51&lt;U+2013&gt;2.<a href="#fnref47" class="footnote-back">↩</a></li>
<li id="fn48"></li>
<li id="fn49"></li>
<li id="fn50"></li>
<li id="fn51">Stamets (1996), p. 38.<a href="#fnref51" class="footnote-back">↩</a></li>
<li id="fn52">Ballesteros <em>et al</em>. (2006), <a href="http://books.google.com/books?id=ovGcMmz5emUC&amp;pg=PA170">p. 170.</a><a href="#fnref52" class="footnote-back">↩</a></li>
<li id="fn53"></li>
<li id="fn54">Stamets (1996), pp. 56&lt;U+2013&gt;8.<a href="#fnref54" class="footnote-back">↩</a></li>
<li id="fn55"></li>
<li id="fn56"></li>
<li id="fn57">Wurst <em>et al</em>. (2002), pp. 10&lt;U+2013&gt;13.<a href="#fnref57" class="footnote-back">↩</a></li>
<li id="fn58"></li>
<li id="fn59"></li>
<li id="fn60">Wurst <em>et al</em>. (2002), pp. 12&lt;U+2013&gt;3.<a href="#fnref60" class="footnote-back">↩</a></li>
<li id="fn61">Wurst <em>et al</em>. (2002), p. 15.<a href="#fnref61" class="footnote-back">↩</a></li>
<li id="fn62"></li>
<li id="fn63"></li>
<li id="fn64"></li>
<li id="fn65"></li>
<li id="fn66"></li>
<li id="fn67"></li>
<li id="fn68"></li>
<li id="fn69"></li>
<li id="fn70"></li>
<li id="fn71"></li>
<li id="fn72"></li>
<li id="fn73"></li>
<li id="fn74"></li>
<li id="fn75"></li>
<li id="fn76"></li>
<li id="fn77"></li>
<li id="fn78"></li>
<li id="fn79"></li>
<li id="fn80"></li>
<li id="fn81"></li>
<li id="fn82"></li>
<li id="fn83"></li>
<li id="fn84"></li>
<li id="fn85"></li>
<li id="fn86"></li>
<li id="fn87"></li>
<li id="fn88"></li>
<li id="fn89"></li>
<li id="fn90"></li>
<li id="fn91"></li>
<li id="fn92"></li>
<li id="fn93"></li>
<li id="fn94"></li>
<li id="fn95"></li>
<li id="fn96"></li>
<li id="fn97"></li>
<li id="fn98"></li>
<li id="fn99"></li>
<li id="fn100"></li>
<li id="fn101"></li>
<li id="fn102"></li>
<li id="fn103"></li>
<li id="fn104"></li>
<li id="fn105"></li>
<li id="fn106"></li>
<li id="fn107"></li>
<li id="fn108"></li>
<li id="fn109"></li>
<li id="fn110"></li>
<li id="fn111"></li>
<li id="fn112"></li>
<li id="fn113"></li>
<li id="fn114"></li>
<li id="fn115"></li>
<li id="fn116"></li>
<li id="fn117">Stamets (1996), <a href="http://books.google.com/books?id=10HiGVo94FUC&amp;pg=PA36">pp. 36&lt;U+2013&gt;41.</a><a href="#fnref117" class="footnote-back">↩</a></li>
<li id="fn118"></li>
<li id="fn119"></li>
<li id="fn120"></li>
<li id="fn121"></li>
<li id="fn122"></li>
<li id="fn123"></li>
<li id="fn124"></li>
<li id="fn125"></li>
<li id="fn126"></li>
<li id="fn127"></li>
<li id="fn128">Ballesteros <em>et al</em>. (2006), <a href="http://books.google.com/books?id=ovGcMmz5emUC&amp;pg=PA171">p. 171.</a><a href="#fnref128" class="footnote-back">↩</a></li>
<li id="fn129"></li>
<li id="fn130"></li>
<li id="fn131"></li>
<li id="fn132"></li>
<li id="fn133"></li>
<li id="fn134"></li>
<li id="fn135"></li>
<li id="fn136"></li>
<li id="fn137"></li>
<li id="fn138"></li>
<li id="fn139">Ballesteros <em>et al</em>. (2006), <a href="http://books.google.com/books?id=ovGcMmz5emUC&amp;pg=PA175">p. 175.</a><a href="#fnref139" class="footnote-back">↩</a></li>
<li id="fn140"></li>
<li id="fn141"></li>
<li id="fn142"></li>
<li id="fn143"></li>
<li id="fn144"></li>
<li id="fn145"></li>
<li id="fn146"></li>
<li id="fn147"></li>
<li id="fn148"></li>
<li id="fn149"></li>
<li id="fn150"></li>
<li id="fn151"><a href="#fnref151" class="footnote-back">↩</a></li>
<li id="fn152"></li>
<li id="fn153"></li>
<li id="fn154"></li>
<li id="fn155"></li>
<li id="fn156"></li>
<li id="fn157"></li>
<li id="fn158"></li>
<li id="fn159"></li>
<li id="fn160">Stafford (1992), p. 273.<a href="#fnref160" class="footnote-back">↩</a></li>
<li id="fn161"></li>
<li id="fn162"></li>
<li id="fn163"></li>
<li id="fn164"></li>
<li id="fn165"></li>
<li id="fn166"></li>
<li id="fn167"></li>
<li id="fn168"></li>
<li id="fn169"></li>
<li id="fn170"></li>
<li id="fn171"></li>
<li id="fn172"></li>
<li id="fn173"></li>
<li id="fn174"></li>
<li id="fn175"></li>
<li id="fn176"></li>
<li id="fn177"></li>
<li id="fn178"></li>
<li id="fn179"></li>
<li id="fn180"></li>
<li id="fn181"></li>
<li id="fn182"></li>
<li id="fn183">Doblin (1991), p. 13.<a href="#fnref183" class="footnote-back">↩</a></li>
<li id="fn184">Doblin (1991), p. 24.<a href="#fnref184" class="footnote-back">↩</a></li>
<li id="fn185"></li>
<li id="fn186"></li>
<li id="fn187"></li>
<li id="fn188"></li>
<li id="fn189"></li>
<li id="fn190"></li>
<li id="fn191"></li>
<li id="fn192"></li>
<li id="fn193"></li>
<li id="fn194"></li>
<li id="fn195"></li>
<li id="fn196">Marley (2010), <a href="http://books.google.com/books?id=KJybhI1yWucC&amp;lpg=PP1&amp;pg=PA179&amp;f=false">pp. 179&lt;U+2013&gt;81</a>.<a href="#fnref196" class="footnote-back">↩</a></li>
<li id="fn197"></li>
<li id="fn198"></li>
<li id="fn199"></li>
<li id="fn200"></li>
<li id="fn201"></li>
<li id="fn202"></li>
<li id="fn203"></li>
<li id="fn204"></li>
<li id="fn205"></li>
<li id="fn206"></li>
<li id="fn207"></li>
<li id="fn208"></li>
<li id="fn209"></li>
<li id="fn210"></li>
<li id="fn211"></li>
<li id="fn212"></li>
<li id="fn213"></li>
<li id="fn214"></li>
<li id="fn215">Boire (2002), p. 25.<a href="#fnref215" class="footnote-back">↩</a></li>
<li id="fn216"></li>
<li id="fn217"></li>
<li id="fn218"></li>
<li id="fn219">Boire (2002), p. 26.<a href="#fnref219" class="footnote-back">↩</a></li>
<li id="fn220"></li>
<li id="fn221"></li>
<li id="fn222"></li>
<li id="fn223">Ballesteros <em>et al</em>. (2006), <a href="http://books.google.com/books?id=ovGcMmz5emUC&amp;pg=PA178">pp. 178&lt;U+2013&gt;9.</a><a href="#fnref223" class="footnote-back">↩</a></li>
<li id="fn224"></li>
<li id="fn225"></li>
<li id="fn226"></li>
<li id="fn227">Boire (2002), pp. 25&lt;U+2013&gt;48.<a href="#fnref227" class="footnote-back">↩</a></li>
<li id="fn228"></li>
<li id="fn229">Marley (2010), <a href="http://books.google.com/books?id=KJybhI1yWucC&amp;pg=PA178">pp. 177&lt;U+2013&gt;8.</a><a href="#fnref229" class="footnote-back">↩</a></li>
<li id="fn230"></li>
</ol>
</section>
